

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Dynamic risk prediction in patients following acute myocardial infarction

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069505
Article Type:	Original research
Date Submitted by the Author:	23-Oct-2022
Complete List of Authors:	<p>Lv, Junxing; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>Wang, Chuang-Shi; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 102300, China.</p> <p>Gao, Xiaojin; Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Cardiology</p> <p>Yang, Jingang; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>Zhang, Xuan; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Cardiology</p> <p>Ye, Yunqing; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Department of Cardiology</p> <p>Dong, Qiuting; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Department of Cardiology</p> <p>Fu, Rui; Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>sun, hui; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>Yan, Xinxin; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Department of Cardiology</p> <p>Zhao, Yanyan; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Medical Research & Biometrics Center</p> <p>Yang, Wang; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital</p> <p>Xu, Haiyan; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Department of Cardiology</p> <p>Yang, Yuejin; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital</p>
Keywords:	Myocardial infarction < CARDIOLOGY, Coronary heart disease < CARDIOLOGY, Coronary intervention < CARDIOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Dynamic risk prediction in patients following acute myocardial infarction

Running title: Dynamic risk prediction after AMI

Junxing Lv, MD^{1,*}, Chuangshi Wang, PhD^{2,*}, Xiaojin Gao, MD, PhD¹, Jingang Yang, MD, PhD¹, Xuan Zhang, MD¹, Yunqing Ye, MD¹, Qiuting Dong, MD, PhD¹, Rui Fu, MD¹, Hui Sun, MD¹, Xinxin Yan, MD, PhD¹, Yanyan Zhao, PhD², Yang Wang, PhD², Haiyan Xu, MD, PhD^{1,†}, and Yuejin Yang, MD, PhD^{1,†}; on behalf of the China Acute Myocardial Infarction Registry study group

¹ Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

² Medical Research & Biometrics Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

* Junxing Lv and Chuangshi Wang contributed equally to this work as joint first authors.

† Haiyan Xu and Yuejin Yang contributed equally to this work as joint corresponding authors.

Correspondence:

Haiyan Xu

Address: No. 167 Beilishi Road, Xicheng District, 100037, Beijing, China.

1
2
3 1 Tel: +86-10-88396082 Fax: +86-10-88396237
4

5
6 2 E-mail: xuhaiyan@fuwaihospital.org
7

8
9 3 Yuejin Yang
10

11
12 4 Address: No. 167 Beilishi Road, Xicheng District, 100037, Beijing, China.
13

14
15 5 E-mail: yangyjfw@126.com
16

17
18 6
19

20
21 7 **Word count**
22

23
24 8 **Abstract: 296 Main text (not including references, tables, and figure legends): 3246**
25

26
27 9
28

29
30 10
31

32
33 11
34

Abstract

Objectives: The risk of adverse events and prognostic factors are changing in different time phases after acute myocardial infarction (AMI). The incidence of adverse events is considerable in the early period after AMI hospitalization. Therefore, dynamic risk prediction is needed to guide post-discharge management of AMI. This study aimed to develop an dynamic prognostic instrument for patients following AMI.

Design: Prospective cohort.

Setting: 108 hospitals in China.

Participants: A total of 23887 patients after AMI in the China Acute Myocardial Infarction registry were included in this analysis.

Primary outcome measures: All-cause mortality.

Results: In multivariable analyses, age, prior stroke, heart rate, Killip class, left ventricular ejection fraction (LVEF), in-hospital percutaneous coronary intervention (PCI), recurrent myocardial ischemia, recurrent myocardial infarction, heart failure (HF) during hospitalization, antiplatelet therapy, and statins at discharge were independently associated with 30-day mortality. Variables related to mortality between 30 days and 2 years included age, prior renal dysfunction, history of HF, AMI classification, heart rate, Killip class, hemoglobin, LVEF, in-hospital PCI, HF during hospitalization, HF worsening within 30 days after discharge, antiplatelet therapy, β blocker, and statins use within 30 days after discharge. The inclusion of adverse events and medications significantly improved the predictive performance of models without these indexes (likelihood ratio test $P < 0.0001$). These two sets of predictors were used to establish dynamic prognostic nomograms for predicting survival in patients with AMI. The C indexes of 30-day and 2-year prognostic nomograms were 0.85 (95% confidence interval [CI]: 0.83-0.88) and 0.83 (95% CI: 0.81-0.84) in derivation cohort,

1
2
3 1 and 0.79 (95% CI: 0.71-0.86) and 0.81 (95% CI: 0.79-0.84) in validation cohort, with
4
5 2 satisfying calibration.
6
7

8 3 **Conclusions:** We established dynamic prognostic models incorporating adverse event and
9
10 4 medications. The nomograms may be useful instruments to help prospective risk assessment
11
12
13 5 and management of AMI.
14
15

16 6 **Trial registration number:** NCT01874691.
17
18
19 7

20
21
22 8 **Keywords:** Myocardial infarction, risk prediction, model, prognosis
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- We developed and validated dynamic prognostic nomograms, which might help prospective risk evaluation and management of patients after acute myocardial infarction (AMI) hospitalization.
- The study demonstrated that both in-hospital and post-discharge adverse events as well as medications were independently associated with mortality, and provided incremental prognostic value over traditional predictors.
- The predictive performance of dynamic prognostic nomograms would be further improved if included more follow-up variables.
- The dynamic prognostic models should be further validated in independent cohorts.

1 2 3 1 **Introduction** 4 5

6 2 Although in-hospital mortality of acute myocardial infarction (AMI) has been decreased in
7
8 3 many countries,^{1,2} risk of adverse events remains considerable in survivors after AMI
9
10 4 hospitalization.³ Previous studies have indicated unsatisfying and imbalanced quality of
11
12 5 secondary prevention medications in clinical practice,^{4,5} which could cause negative impact
13
14 6 on prognosis of AMI patients. Individualized risk assessment may aid in decision making of
15
16 7 long-term therapeutic strategies for patients after AMI. However, the existing risk prediction
17
18 8 tools, which are mainly based on data collected at admission, fail to consider the changing
19
20 9 nature of adverse events and medications after AMI hospitalization,^{6,7} and therefore may not
21
22 10 be appropriate to guide long-term management. Dynamic risk assessment may help improve
23
24 11 the quality of long-term management for patients following AMI.
25
26
27
28
29

30 12 Although several studies sought to forecast mortality dynamically in patients with acute
31
32 13 coronary syndromes,⁸⁻¹¹ prognostic components of these models were obtained during
33
34 14 hospitalization, without taking follow-up adverse events and medications into consideration.
35
36 15 Dynamic prognostic instruments designed to help risk reassessment should include
37
38 16 post-discharge information which is associated with outcomes. In this study, we aimed to
39
40 17 establish and validate dynamic risk prediction models, visualized by nomograms, which
41
42 18 included in-hospital and post-discharge adverse events and medications, to assist in
43
44 19 prognostic evaluation and decision-making of secondary prevention strategies in patients
45
46 20 following AMI.
47
48
49
50

51 21 52 53 54 22 **Methods** 55 56

57 23 *Study population* 58 59 60

1
2
3 1 The data for the present study were from the China Acute Myocardial Infarction (CAMI)
4
5 2 registry. The design of the CAMI registry has been described and published elsewhere.¹²
6
7
8 3 Briefly, 108 hospitals from 31 provinces and municipalities throughout Mainland China were
9
10 4 included in this prospective, nationwide, multicenter registry. Consecutive patients with AMI
11
12 5 were enrolled in the registry and the final diagnosis of patients must meet the third Universal
13
14 6 Definition for Myocardial Infarction (2012).¹³ All types of AMI were eligible for the CAMI
15
16 7 registry, except type 4a and type 5. Presenting characteristics, medical history, laboratory
17
18 8 results, medications, and clinical outcomes were collected according to the ACC/AHA Task
19
20 9 Force on clinical data standards and NCDR-ACTION-GWTG element dictionary.
21
22
23

24 10 Patients registered in the CAMI registry from January 2013 to September 2014 were
25
26 11 included in this study. Those with invalid diagnosis (n=1312), who were transferred out
27
28 12 (n=1181) or died during hospitalization (n=1690) were excluded. The remaining population
29
30 13 (n=23887) was divided randomly according to 2:1 ratio into derivation (n=15925) and
31
32 14 validation (n=7962) cohorts for developing and validating a 30-day risk prediction model.
33
34 15 After further excluding patients who died within 30 days after discharge (n=293) and those
35
36 16 with missing data on 30-day medication use (n=5391), the remaining derivation (n=12136)
37
38 17 and validation (n=6067) cohorts were used for establishing and testing a 2-year risk prediction
39
40 18 model (online supplemental figure 1).
41
42
43
44
45
46
47
48

49 20 ***Definitions***

50
51 21 Standard definitions of adverse events have been described elsewhere in detail.¹⁴ Taking a
52
53 22 medication within 30 days means using the medication during this period after discharge
54
55 23 without discontinuation.
56
57
58
59
60

Follow-up and endpoints

Patients were followed by clinical visits or telephone call at 30 days, 6 months, 12 months, 18 months, and 24 months. Adverse events (such as death, recurrent myocardial infarction, and heart failure worsening) and medications at follow-up time points were collected by trained cardiologists or cardiovascular fellows. The primary endpoints of this analysis were all-cause mortality within 30 days after AMI hospitalization (for establishing 30-day risk prediction model) and mortality between 30 days and 2 years (for establishing 2-year risk prediction model).

Statistical analysis

Categorical variables were summarized as frequencies and percentages, and compared by chi-square or Fisher exact test, as appropriate. Continuous variables were expressed as mean \pm standard deviation or medians (interquartile range) according to data distributions, and compared by student t or nonparametric test. Kaplan-Meier curve and density plots were used to depict the changing nature of risk after AMI hospitalization.

The derivation cohort was used to screen predictors of 30-day mortality and mortality between 30 days and 2 years. The associations between variables, including age, sex, body mass index (BMI), diabetes, hypertension, hyperlipidemia, smoking, prior angina pectoris, prior myocardial infarction, prior heart failure, prior stroke, prior peripheral artery disease, prior percutaneous coronary intervention (PCI), prior coronary artery bypass graft (CABG), prior renal dysfunction, chronic obstructive pulmonary disease, symptom onset to admission time, heart rate, systolic blood pressure, Killip class, cardiac arrest at admission, diagnosis, anterior wall involvement, creatinine clearance, hemoglobin, leukocyte count, left ventricular ejection fraction (LVEF), in-hospital PCI, in-hospital CABG, heart failure, recurrent

1
2
3 1 myocardial ischemia, recurrent myocardial infarction, stroke, other bleeding events (bleeding
4
5 2 events not including cerebral hemorrhage) during hospitalization, antiplatelet therapy at
6
7
8 3 discharge, statins at discharge, β blockers at discharge, and angiotensin converting enzyme
9
10 4 inhibitor (ACEI) or angiotensin II receptor blocker (ARB) at discharge, and 30-day mortality
11
12 5 were first assessed in univariable Cox regression models. For obtaining prognostic factors of
13
14 6 mortality between 30 days and 2 years, the associations of adverse events within 30 days
15
16 7 (recurrent myocardial infarction and heart failure worsening) and 30-day medications
17
18 8 (antiplatelet therapy, statins, β blockers, and ACEI/ARB) with mortality were also assessed in
19
20 9 univariable Cox models besides variables mentioned previously. Subsequently, the least
21
22 10 absolute shrinkage and selection operator (LASSO) method was adopted to select predictors
23
24 11 of short-term and long-term mortality respectively from variables with $P \leq 0.1$ in univariable
25
26 12 analysis. The selected predictors were used to establish dynamic risk prediction models by
27
28 13 multivariable Cox regression model. The relative importance of these variables was ranked
29
30 14 according to the proportion of explainable log-likelihood ratio χ^2 statistics.

31
32
33
34
35
36 15 To analyze the incremental prognostic value of adverse events and medications over
37
38 16 traditional predictive indexes, we compared the predictive performance between models with
39
40 17 or without adverse events and medications using C index, net reclassification index (NRI),
41
42 18 integrated discrimination improvement index (IDI), likelihood ratio test, and Bayesian
43
44 19 information criteria (BIC). The clinical utilities of models were compared by decision curve
45
46 20 analysis. Predictive performance was also compared between 30-day risk model or 2-year risk
47
48 21 model and the Global Registry of Acute Coronary Events (GRACE) risk score to further
49
50 22 analyze the additional value of the dynamic models beyond existing prognostic tool.

51
52
53
54
55 23 Two prognostic nomograms, which could make complex predictive formulas friendly to
56
57 24 use in clinical practice, were constructed based on the regression coefficients of predictors for
58
59 25 mortality using the “rms” package of R software. Discrimination and calibration of the

1
2
3 1 nomograms were assessed by C index and calibration curves presenting the relationship
4
5 2 between observed and predicted survival probabilities in both derivation and validation
6
7 3 cohorts. Predictive performance of models was also evaluated in subgroups of patients
8
9 4 according to age, sex, diabetes, AMI classification, and in-hospital PCI.

10
11
12
13 5 Before multivariable analysis, we calculated variance inflation factor to examine
14
15 6 multicollinearity issue. Multiple imputation was used to generate 5 datasets without missing
16
17 7 values. The LASSO method was performed in each dataset. Only variables selected by
18
19 8 LASSO method in all 5 datasets were included in final dynamic prognostic models. Results of
20
21 9 Cox regression models were reported as hazard ratios (HR) with 95% confidence intervals
22
23 10 (CI). A two-tailed $P < 0.05$ was considered statistically significant. Statistical analyses were
24
25 11 performed using R version 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria)
26
27 12 and SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

31 32 13 33 34 35 14 ***Patient and public involvement***

36
37
38 15 Patients or the public were not involved directly in the design, conduct, reporting or
39
40 16 dissemination plans of our research.

41 42 43 17 44 45 46 18 **Results**

47
48
49 19 Baseline characteristics, medications, and outcomes of derivation and validation cohorts were
50
51 20 summarized in table 1 and online supplemental table 1. Variables were comparable between
52
53 21 derivation and validation cohorts except β blockers at discharge. Rates of 30-day mortality
54
55 22 among hospital survivors in derivation and validation cohorts were 1.2% (190/15925 patients)
56
57 23 and 1.3% (103/7962 patients), respectively. Rates of mortality between 30 days and 2 years
58
59
60

1
2
3 1 were 6.1% (740/12136 patients) and 5.7% (345/6067 patients). The Kaplan-Meier curve and
4
5 2 density plots showed the changing risk of death and recurrent myocardial infarction within 2
6
7 3 years after AMI hospitalization (online supplemental figure 2 and 3).
8
9

10 4 11 12 13 14 5 ***Predictors of 30-day mortality in patients after AMI***

15
16 6 Univariable analysis of the associations between variables and 30-day mortality was presented
17
18 7 in online supplemental table 2. In the LASSO-based Cox regression model, age, prior stroke,
19
20 8 heart rate, Killip class, LVEF, in-hospital PCI, in-hospital recurrent myocardial ischemia,
21
22 9 in-hospital recurrent myocardial infarction, in-hospital heart failure, antiplatelet therapy, and
23
24 10 statins at discharge were independently associated with 30-day mortality (online supplemental
25
26 11 figure 4 to 8; table 2). The relative importance of these predictors was ranked and shown in
27
28 12 online supplemental figure 9.
29
30
31
32
33
34
35

36 14 ***Predictors of 2-year mortality for 30-day survivors after AMI hospitalization***

37
38
39 15 Univariable analysis of mortality between 30 days and 2 years after AMI hospitalization was
40
41 16 shown in online supplemental table 3. In the LASSO-based Cox regression model, age, prior
42
43 17 renal dysfunction, history of heart failure, AMI classification, heart rate, Killip class,
44
45 18 hemoglobin, LVEF, in-hospital PCI, in-hospital heart failure, heart failure worsening within
46
47 19 30 days, antiplatelet therapy, β blocker, and statins within 30 days were identified as
48
49 20 predictors of mortality (online supplemental figure 10 to 14; table 3). The relative importance
50
51 21 of these predictors was ranked and presented in online supplemental figure 15.
52
53
54
55
56
57
58

59 23 ***Incremental prognostic value of adverse events and medications***

60

1
2
3 1 The inclusion of in-hospital recurrent myocardial ischemia, in-hospital recurrent myocardial
4
5 2 infarction, in-hospital heart failure, antiplatelet therapy, and statins at discharge significantly
6
7
8 3 improved the predictive power of 30-day risk prediction model (table 4; 30-day model 1 vs
9
10 4 30-day model 0, C index, 0.855 [0.830-0.879] vs 0.822 [0.796-0.848]; NRI [95%CI], 0.445
11
12 5 [0.339-0.523], P<0.0001; IDI [95%CI], 0.040 [0.025-0.074], P<0.0001; likelihood ratio test
13
14 6 P<0.0001; BIC, 3434.091 vs 3350.882). In the 2-year risk prediction model, heart failure
15
16 7 worsening within 30 days, antiplatelet, β blocker, and statins within 30 days also provided
17
18 8 additional prognostic value over predictive indexes obtained during hospitalization (table 5).
19
20 9 The decision curve analysis further demonstrated better clinical utilities after adding adverse
21
22 10 events and medications into 30-day and 2-year risk models (online supplemental figure 16).
23
24
25
26
27 11
28
29

30 12 ***Comparisons of prognostic models and GRACE risk score***

31
32
33 13 For predicting 30-day mortality, the 30-day risk prediction model showed significantly better
34
35 14 predictive performance than the GRACE risk score (30-day risk model vs GRACE score, C
36
37 15 index, 0.855 [0.830-0.879] vs 0.771 [0.740-0.802]; NRI [95%CI], 0.412 [0.307-0.485],
38
39 16 P<0.0001; IDI [95%CI], 0.048 [0.032-0.090], P<0.0001; BIC, 3267.271 vs 3402.578).
40
41 17 Similarly, when predicting 2-year mortality, the 2-year risk prediction model also performed
42
43 18 better than the GRACE risk score (2-year risk model vs GRACE score, C index, 0.825
44
45 19 [0.811-0.839] vs 0.798 [0.783-0.813]; NRI [95%CI], 0.191 [0.147-0.257], P<0.0001; IDI
46
47 20 [95%CI], 0.041 [0.031-0.057], P<0.0001; BIC, 12540.559 vs 12697.527). The decision curve
48
49 21 analysis further demonstrated better clinical utilities of both 30-day and 2-year risk models
50
51 22 than CRACE score (online supplemental figure 17).
52
53
54
55
56 23
57
58
59 24

60 24 ***Nomograms for dynamic risk prediction***

1
2
3 1 Two nomograms were created by assigning a weighted score based on regression coefficients
4
5 2 of each prognostic index for calculating 30-day and 2-year survival probabilities respectively.
6
7 3 All observed values of a prognostic index corresponded vertically to points on the top scale.
8
9 4 The sum of points for each index was plotted on the “Total points” scale, and corresponded to
10
11 5 survival probability at the bottom (figure 1 and 2).
12
13
14

15 6 The 30-day prognostic nomogram achieved high discrimination in both derivation and
16
17 7 validation cohorts, with C indexes of 0.85 (95% CI: 0.83-0.88) and 0.79 (95% CI: 0.71-0.86)
18
19 8 respectively. The calibration curves presenting the concordance between observed and
20
21 9 predicted 30-day survival probability in two cohorts also showed satisfying calibration of the
22
23 10 model (online supplemental figure 18). In addition, the 30-day prognostic nomogram
24
25 11 achieved moderate to high discrimination (C indexes: 0.74 to 0.83) in subsets according to
26
27 12 age, sex, diabetes, AMI classification, and PCI (online supplemental table 4).
28
29
30
31

32 13 The C indexes of 2-year prognostic nomogram were 0.83 (95% CI: 0.81-0.84) and 0.81
33
34 14 (95% CI: 0.79-0.84) in derivation and validation cohorts, respectively. The calibration curves
35
36 15 demonstrated excellent calibration of the nomogram in both derivation and validation cohorts
37
38 16 (online supplemental figure 19). In aforementioned subgroups of patients, the model
39
40 17 discrimination was acceptable (C index: 0.66 to 0.83, online supplemental table 5).
41
42
43
44
45
46

47 19 **Discussion**

48
49
50 20 Using data from a large, prospective, multicenter registry, we screened eleven predictors of
51
52 21 30-day mortality, and fourteen variables, including heart failure worsening and medications
53
54 22 within 30 days, related to mortality between 30 days and 2 years in patients after AMI
55
56 23 hospitalization. These two sets of predictors were used to develop prognostic nomograms
57
58 24 which could predict post-discharge mortality for AMI patients in different time phases. The
59
60

1
2
3 1 nomograms showed satisfying discrimination and calibration in both derivation and validation
4
5 2 cohorts. This is a novel dynamic prognostic tool which can serve for prospective risk
6
7 3 assessment and guide long-term management of patients after AMI.
8
9

10 4 A series of risk models have been developed to predict mortality in patients with acute
11
12 5 coronary syndromes.^{6,7,15} These models mainly included prognostic factors obtained at
13
14 6 admission, and provided a fixed estimate of survival probability for a given patient. This
15
16 7 working mode of prognostic models was helpful for screening high-risk patients and
17
18 8 determining therapeutic strategies after admission. However, the incidence of adverse
19
20 9 cardiovascular events remained considerable after in-hospital management of AMI.
21
22 10 Accumulating evidence has implied that a larger proportion of adverse events occurred in the
23
24 11 early phase after AMI hospitalization,¹⁶ which reflected the changing risk following AMI and
25
26 12 highlighted the importance of risk reassessment during follow-up. Although some prognostic
27
28 13 models, such as the Global Registry of Acute Coronary Events (GRACE) risk score and
29
30 14 dynamic Thrombolysis In Myocardial Infarction (TIMI) risk score, could be used to assess
31
32 15 survival at discharge,^{6,9} none of them could improve survival estimates during follow-up.
33
34 16 Considering the higher risk of adverse events in the early period than that at the late stage
35
36 17 after AMI hospitalization (online supplemental figure 2 and 3), we chose 30 days, which was
37
38 18 also one of routine follow-up points after AMI hospitalization in clinical practice, as the time
39
40 19 point of risk reassessment to establish dynamic risk prediction models.
41
42
43
44
45
46
47

48 20 The first model, which was developed to assess 30-day survival at discharge in patients
49
50 21 after AMI, included variables related to patients' demographics, hemodynamics, left
51
52 22 ventricular systolic function, treatment, in-hospital adverse events, and medications at
53
54 23 discharge. Previous studies have established several prognostic models, such as Platelet
55
56 24 glycoprotein IIb/IIIa in Unstable agina: Receptor Suppression Using Integrilin (eptifibatide)
57
58 25 Therapy (PURSUIT) and Zwolle risk scores,^{17,18} to predict 30-day mortality in patients with
59
60

1
2
3 1 acute coronary syndromes. However, these models mainly used patient characteristics,
4
5 2 clinical presentations at admission as well as angiographic features as prognostic indexes. The
6
7
8 3 present study showed that recurrent myocardial ischemia, recurrent myocardial infarction,
9
10 4 heart failure during AMI hospitalization, antiplatelet therapy, and statins use at discharge
11
12 5 were independently associated with short-term mortality after discharge, and provided
13
14 6 significantly incremental prognostic information over traditional predictive indexes.
15
16
17 7 Therefore, these adverse events and medications were included in the novel 30-day prognostic
18
19 8 model, which might assist in decision-making of post-discharge management.

22 9 For the second model assessing 2-year survival in 30-day survivors, we screened new
23
24 10 predictors including heart failure worsening within 30 days, antiplatelet therapy, β blocker,
25
26 11 and statins use within 30 days after discharge. A prior study showed that mortality rate of
27
28 12 patients with an early recurrent myocardial infarction (recurrent myocardial infarction within
29
30 13 90 days of discharge) was nearly 50% within 5 years.¹⁹ In the present study, we observed that
31
32 14 the recurrent myocardial infarction and heart failure worsening within 30 days after discharge
33
34 15 were associated with >3-fold and >4.5-fold increase of 2-year mortality risk respectively in
35
36 16 univariable analysis, and heart failure worsening, which was included in 2-year prognostic
37
38 17 nomogram, was a statistically significant prognostic index in multivariable analysis. To our
39
40 18 best knowledge, this is the first prognostic instrument taking follow-up adverse event after
41
42 19 AMI into consideration. In addition, although some studies analyzed the prognostic impact of
43
44 20 secondary prevention implementation in patients after AMI,^{20,21} follow-up medications have
45
46 21 not been considered as predictive indexes in risk models for AMI so far. For some patients,
47
48 22 not taking optimal medical care within 30 days after discharge could be explained by poor
49
50 23 medication adherence after AMI, which was a problem for both developed and developing
51
52 24 countries.²¹⁻²³ A study found that about 30% of patients with myocardial infarction who
53
54 25 underwent PCI in the United States reported suboptimal adherence to prescribed medications
55
56
57
58
59
60

1
2
3 1 in six weeks after hospitalization.²³ Data from the China PEACE Prospective AMI study also
4
5 2 showed a similar percentage of AMI patients did not take medications as prescribed in the
6
7 3 first month after discharge.²¹ Patients with early medication nonadherence not only suffered a
8
9 4 higher risk of early adverse events, but might not comply with long-term secondary
10
11 5 prevention measures, and therefore had poorer long-term prognosis. Another situation was
12
13 6 that patients were not prescribed with some medications by physicians, due to
14
15 7 contraindications or high risk of side effects. However, lack of secondary prevention
16
17 8 medications after AMI still meant a higher risk of cardiovascular adverse events in these
18
19 9 patients. Indeed, our analysis showed that insufficient use of antiplatelet therapy, β blocker,
20
21 10 and statins within 30 days after AMI hospitalization had significant negative impact on 2-year
22
23 11 survival. The inclusion of follow-up medications and adverse events improved risk prediction
24
25 12 of 2-year prognostic model.

26
27
28
29
30
31 13 The present study showed that the dynamic prognostic nomograms achieved satisfying
32
33 14 discrimination and calibration, and performed well in subgroups of patients according to age,
34
35 15 sex, diabetes, AMI classification, and PCI. The clinical usefulness of nomograms was
36
37 16 confirmed by decision curve analysis. Prognostic nomograms have been used for risk
38
39 17 prediction of cancer and cardiovascular diseases.²⁴⁻²⁸ The nomograms in this study could
40
41 18 assist in dynamic prognostic evaluation in routine clinical practice. Using the nomogram for
42
43 19 prediction of 30-day survival, physicians can identify high-risk patients at discharge. Then,
44
45 20 the second nomogram can be used to reassess survival probabilities of 30-day survivors, and
46
47 21 may guide decision-making of long-term follow-up intensity and strategies of medical care.
48
49
50
51
52
53
54

55 23 **Limitations**

56
57
58
59
60

1
2
3 1 Several important limitations in this study should be mentioned. First, besides variables
4
5 2 during hospitalization, heart failure worsening and medications within 30 days after discharge
6
7 3 were included in the model for prediction of 2-year mortality. However, laboratory or
8
9 4 echocardiographic indexes, such as biomarkers of inflammation, N-terminal pro-B-type
10
11 5 natriuretic peptide, or LVEF, were not obtained during follow-up. These variables may further
12
13 6 improve the predictive performance of dynamic models. Second, although the present study
14
15 7 showed the feasibility of assessing 2-year prognosis at 30 days after discharge, risk
16
17 8 reassessment was a serial process and should be done repeatedly beyond early phase after
18
19 9 AMI hospitalization. Finally, our dynamic models were only validated in the CAMI registry.
20
21
22
23
24 10 Further tests for generalizability in external cohorts are needed.
25
26
27 11

28 29 12 **Conclusions**

30
31
32 13 The dynamic risk prediction tool consisted of a short-term prognostic model and a long-term
33
34 14 prognostic model for patients following AMI. Taking the changing nature of adverse events
35
36 15 and medications into consideration, the models can serve prospective risk stratification and
37
38 16 guide post-discharge management of AMI. Dynamic risk prediction may play an important
39
40 17 role in therapeutic decision-making and quality improvement of secondary prevention after
41
42 18 AMI hospitalization.
43
44
45
46
47 19

48 49 20 **Acknowledgments**

50
51
52 21 We appreciate all staff and investigators for their contributions to the CAMI registry.
53
54
55 22

56 57 58 23 **Contributors**

59
60

1
2
3 1 HX and YYang contributed significantly to the conception, design, and conduction of this
4
5 2 study. JL and CW wrote the initial manuscript. CW, YZ, and YW provided strong support in
6
7 3 statistical analysis. JL, CW, XG, JY, XZ, YYe, QD, RF, HS, XY, YZ, YW, HX, and YYang
8
9 4 contributed significantly to revisions of manuscript, analysis, and interpretation of data. All
10
11 5 authors contributed substantially to this study and approved its submission.
12
13
14
15 6

17 18 7 **Funding**

19
20
21 8 This work was supported by the Twelfth Five-Year Planning Project of the Scientific and
22
23 9 Technological Department of China [grant number 2011BAI11B02] and Beijing Nova
24
25 10 Program [grant number Z211100002121063].
26
27
28
29 11

30 31 32 12 **Competing Interests**

33
34
35 13 None declared.
36
37
38 14

39 40 41 15 **Patient consent for publication**

42
43
44 16 Not required.
45
46
47 17

48 49 50 18 **Ethics approval**

51
52 19 The CAMI registry conformed to the ethical guidelines of the Declaration of Helsinki, and
53
54 20 was approved by the institutional review board central committee at Fuwai Hospital, National
55
56 21 Center for Cardiovascular Diseases of China. Written informed consents were given by
57
58 22 eligible patients before registration.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9

Data Availability Statement

Data are available on reasonable request from the corresponding authors.

References

1. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J* 2008;156:1045-55.
2. Yamamoto T, Yoshida N, Takayama M; Tokyo CCU Network. Temporal trends in acute myocardial infarction incidence and mortality between 2006 and 2016 in Tokyo - Report from the Tokyo CCU Network. *Circ J* 2019;83:1405-9.
3. Chaudhry SI, Khan RF, Chen J, et al. National trends in recurrent AMI hospitalizations 1 year after acute myocardial infarction in Medicare beneficiaries: 1999-2010. *J Am Heart Assoc* 2014;3:e001197.
4. Ergatoudes C, Thunström E, Rosengren A, et al. Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome. *BMC Cardiovasc Disord* 2016;16:226.
5. Zhao Q, Xu H, Zhang X, et al. Current status and hospital-level differences in care and outcomes of patients with acute non-ST-segment elevation myocardial infarction in China: insights from China Acute Myocardial Infarction Registry. *Front Cardiovasc Med* 2022;8:800222.
6. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. *JAMA* 2004;291:2727-33.
7. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. *JAMA* 2000;284:835-42.

- 1
2
3 1 8. Chang WC, Boersma E, Granger CB, et al. Dynamic prognostication in non-ST-elevation
4
5 2 acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. *Am Heart J*
6
7 3 2004;148:62-71.
- 8
9
10 4 9. Amin ST, Morrow DA, Braunwald E, et al. Dynamic TIMI risk score for STEMI. *J Am*
11
12 5 *Heart Assoc* 2013;2:e003269.
- 13
14
15 6 10. Chang WC, Kaul P, Fu Y, et al. Forecasting mortality: dynamic assessment of risk in
16
17 7 ST-segment elevation acute myocardial infarction. *Eur Heart J* 2006;27:419-26.
- 18
19
20 8 11. Westerhout CM, Pieper KS, James SK, et al. Dynamic modeling of 90-day mortality in
21
22 9 ST-elevation myocardial infarction patients undergoing primary percutaneous coronary
23
24 10 intervention. *Am Heart J* 2013;165:354-62.e2.
- 25
26
27 11 12. Xu H, Li W, Yang J, et al. Tal Infarction (CAMI) Registry: a national long-term
28
29 12 registry-research-education integrated platform for exploring acute myocardial infarction
30
31 13 in China. *Am Heart J* 2016;175:193-201.e3.
- 32
33
34 14 13. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial
35
36 15 infarction. *Circulation* 2012;126:2020-35.
- 37
38
39 16 14. Xu H, Yang Y, Wang C, et al. Association of hospital-level differences in care with
40
41 17 outcomes among patients with acute ST-segment elevation myocardial infarction in
42
43 18 China. *JAMA Netw Open* 2020;3:e2021677.
- 44
45
46 19 15. McNamara RL, Kennedy KF, Cohen DJ, et al. Predicting in-hospital mortality in
47
48 20 patients with acute myocardial infarction. *J Am Coll Cardiol* 2016;68:626-35.
- 49
50
51 21 16. Song J, Murugiah K, Hu S, et al. Incidence, predictors, and prognostic impact of recurrent
52
53 22 acute myocardial infarction in China. *Heart* 2020;107:313-8.
- 54
55
56
57
58
59
60

- 1
2
3 1 17. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute
4
5 2 coronary syndromes without persistent ST-segment elevation. Results from an
6
7 3 international trial of 9461 patients. The PURSUIT Investigators. *Circulation*
8
9 4 2020;101:2557-67.
10
11
12
13 5 18. De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of patients with
14
15 6 acute myocardial infarction treated with primary angioplasty: implications for early
16
17 7 discharge. *Circulation* 2004;109:2737-43.
18
19
20 8 19. Nair R, Johnson M, Kravitz K, et al. Characteristics and outcomes of early recurrent
21
22 9 myocardial infarction after acute myocardial infarction. *J Am Heart Assoc*
23
24 10 2021;10:e019270.
25
26
27
28 11 20. Chow CK, Brieger D, Ryan M, et al. Secondary prevention therapies in acute coronary
29
30 12 syndrome and relation to outcomes: observational study. *Heart Asia* 2019;11:e011122.
31
32
33 13 21. Shang P, Liu GG, Zheng X, et al. Association between medication adherence and 1-year
34
35 14 major cardiovascular adverse events after acute myocardial infarction in China. *J Am*
36
37 15 *Heart Assoc* 2019;8:e011793.
38
39
40
41 16 22. Rymer J, McCoy LA, Thomas L, et al. Persistence of evidence-based medication use
42
43 17 after discharge from academic versus nonacademic hospitals among patients with
44
45 18 non-ST-segment elevation myocardial infarction. *Am J Cardiol* 2014;114:1479-84.
46
47
48
49 19 23. Mathews R, Peterson ED, Honeycutt E, et al. Early medication nonadherence after acute
50
51 20 myocardial infarction: insights into actionable opportunities from the Treatment with
52
53 21 ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events
54
55 22 after Acute Coronary Syndrome (TRANSLATE-ACS) Study. *Circ Cardiovasc Qual*
56
57 23 *Outcomes* 2015;8:347-56.
58
59
60

- 1
2
3 1 24. Yan B, Su BB, Bai DS, et al. A practical nomogram and risk stratification system
4
5 2 predicting the cancer-specific survival for patients with early hepatocellular carcinoma.
6
7 3 *Cancer Med* 2021;10:496-506.
8
9
10 4 25. Liu H, Lv L, Qu Y, et al. Prediction of cancer-specific survival and overall survival in
11
12 5 middle-aged and older patients with rectal adenocarcinoma using a nomogram model.
13
14 6 *Transl Oncol* 2021;14:100938.
15
16
17
18 7 26. Ó Hartaigh B, Gransar H, Callister T, et al. Development and validation of a
19
20 8 simple-to-use nomogram for predicting 5-, 10-, and 15-year survival in asymptomatic
21
22 9 adults undergoing coronary artery calcium scoring. *JACC Cardiovasc Imaging*
23
24 10 2018;11:450-8.
25
26
27
28 11 27. Guo Q, Wu M, Li H, et al. Development and validation of a prognostic nomogram for
29
30 12 myocardial infarction patients in intensive care units: a retrospective cohort study. *BMJ*
31
32 13 *Open* 2020;10:e040291.
33
34
35
36 14 28. Wang H, Liu D, Liang H, et al. A nomogram for predicting survival in patients with
37
38 15 colorectal cancer incorporating cardiovascular comorbidities. *Front Cardiovasc Med*
39
40 16 2022;9:875560.
41
42
43
44 17
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline characteristics, medications, and outcomes of cohorts for developing and validating 30-day prognostic model

Variables	Derivation cohort (n=15925)	Validation cohort (n=7962)	P value
Demographics			
Age, yrs	62.27±12.36	62.54±12.29	0.1122
Female	3878 (24.4)	1940 (24.4)	0.9809
BMI, kg/m ²	24.13±3.05	24.08±3.04	0.2475
Medical history			
Diabetes	2943 (19.6)	1505 (20.0)	0.4491
Hypertension	7873 (51.2)	3897 (50.8)	0.4970
Hyperlipidemia	1154 (8.5)	569 (8.3)	0.6198
Current smoker	7083 (45.7)	3483 (44.8)	0.2257
Prior angina pectoris	4044 (27.8)	1994 (27.4)	0.4987
Prior myocardial infarction	1083 (7.4)	553 (7.5)	0.7122
Prior heart failure	329 (2.2)	169 (2.3)	0.7723
Prior stroke	1330 (8.8)	711 (9.4)	0.1367
Prior peripheral artery disease	96 (0.6)	46 (0.6)	0.8073
Prior PCI	753 (5.0)	381 (5.1)	0.8669
Prior CABG	56 (0.4)	36 (0.5)	0.2450

Prior renal dysfunction	197 (1.3)	94 (1.3)	0.6985
COPD	279 (1.9)	142 (1.9)	0.8702
Presenting characteristics			
Symptom onset to admission time			0.1515
0-6h	7398 (47.0)	3625 (46.0)	
>6h	8330 (53.0)	4247 (54.0)	
Heart rate, beats/min	77.45±18.07	77.84±18.03	0.1131
Systolic blood pressure	129.48±25.01	129.94±25.26	0.1865
Killip class			0.5017
I	11836 (76.2)	5903 (75.8)	
II-IV	3694 (23.8)	1883 (24.2)	
Cardiac arrest at admission	128 (0.8)	77 (1.0)	0.2092
AMI classification			0.4680
STEMI	12051 (75.7)	5991 (75.2)	
NSTEMI	3874 (24.3)	1971 (24.8)	
Anterior wall involvement	7406 (47.7)	3696 (47.5)	0.8342
Laboratory results			
Creatinine, µmol/L	74.90 (62.00, 90.00)	74.60 (62.00, 90.40)	0.9110
Creatinine clearance, ml/min	83.83 (61.61, 109.00)	83.70 (61.52, 108.71)	0.3404

Hemoglobin, g/L	136.23±21.09	136.07±20.94	0.5897
Leukocyte count, ×10 ⁹ /L	10.09±3.69	10.04±3.60	0.4052
LVEF, %	53.84±10.07	53.81±10.08	0.8202
In-hospital treatment			
PCI	8951 (57.9)	4432 (57.2)	0.3550
CABG	127 (0.8)	76 (1.0)	0.2190
Adverse events during hospitalization			
New-onset heart failure	2082 (13.5)	1035 (13.4)	0.8803
Recurrent myocardial ischemia	384 (2.5)	166 (2.2)	0.1124
Recurrent myocardial infarction	61 (0.4)	22 (0.3)	0.1781
Stroke	90 (0.6)	40 (0.5)	0.5349
Other bleeding events	236 (1.5)	121 (1.6)	0.8112
Medications at discharge			
Antiplatelet therapy			0.4017
Dual antiplatelet therapy	13212 (87.6)	6571 (87.1)	
Single antiplatelet therapy	1261 (8.4)	648 (8.6)	
None	603 (4.0)	327 (4.3)	
Statins	13846 (91.8)	6976 (92.4)	0.1115
β blockers	10341 (68.6)	5006 (66.3)	0.0006

	ACEI/ARB	8642 (57.3)	4326 (57.3)	0.9937
--	----------	-------------	-------------	--------

1 Values are shown as mean \pm standard deviation, median (interquartile range), or number (%)
2 without imputation of missing data. BMI, body mass index; PCI, percutaneous coronary
3 intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary
4 disease; AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial
5 infarction; NSTEMI, non-ST-segment elevation myocardial infarction; LVEF, left ventricular
6 ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II
7 receptor blocker.

8

1 **Table 2. Multivariable analysis of 30-day mortality in the derivation cohort**

	All-cause death	
	Adjusted HR (95% CI)	P value
Age (per 1 year increase)	1.035 (1.021, 1.049)	<0.0001
Prior stroke (vs no)	1.560 (1.091-2.231)	0.0148
Heart rate (per 1beat/min increase)	1.006 (1.000-1.012)	0.0497
Killip class II -IV(vs I)	1.528 (1.115-2.094)	0.0083
LVEF (per 1% increase)	0.969 (0.955, 0.982)	<0.0001
In-hospital PCI (vs no)	0.441 (0.307, 0.634)	<0.0001
In-hospital recurrent myocardial ischemia (vs no)	1.711 (1.019-2.871)	0.0421
In-hospital recurrent myocardial infarction (vs no)	4.572 (2.121-9.859)	0.0001
In-hospital heart failure (vs no)	2.869 (2.065-3.986)	<0.0001
Antiplatelet therapy at discharge (vs dual antiplatelet therapy)		
Single antiplatelet therapy	0.791 (0.491-1.275)	0.3358
None	2.363 (1.395-4.003)	0.0014
Statins at discharge (vs no)	2.009 (1.258-3.208)	0.0035

2 LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; HR, hazard
3 ratio; CI, confidence interval.

4

1
2
3 **1 Table 3. Multivariable analysis of mortality after 30 days in the derivation cohort**
4
5

	All-cause death	
	Adjusted HR (95% CI)	P value
Age (per 1 year increase)	1.052 (1.045-1.060)	<0.0001
Prior renal dysfunction (vs no)	1.539 (1.076-2.201)	0.0181
History of heart failure (vs no)	1.501 (1.160-1.943)	0.0020
STEMI (vs NSTEMI)	0.747 (0.639-0.873)	0.0002
Heart rate (per 1 beat/min increase)	1.008 (1.005-1.011)	<0.0001
Killip class II -IV(vs I)	1.330 (1.129-1.566)	0.0006
Hemoglobin (per 1g/L increase)	0.993 (0.990-0.996)	<0.0001
LVEF (per 1% increase)	0.971 (0.964-0.978)	<0.0001
In-hospital PCI (vs no)	0.423 (0.351-0.510)	<0.0001
In-hospital heart failure(vs no)	1.287 (1.085-1.525)	0.0037
Heart failure worsening within 30 days (vs no)	1.675 (1.258-2.229)	0.0004
Antiplatelet therapy within 30 days (vs dual antiplatelet therapy)		
Single antiplatelet therapy	1.107 (0.911-1.345)	0.3084
None	1.430 (1.055-1.937)	0.0211
β blocker within 30 days (vs yes)	1.271 (1.085-1.491)	0.0031
Statins within 30 days (vs yes)	1.191 (0.908-1.561)	0.2075

1
2
3 1 STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation
4
5 2 myocardial infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
6
7 3 intervention; HR, hazard ratio; CI, confidence interval.
8
9
10
11 4
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4. Comparison of 30-day prognostic models with or without adverse events and medications

	30-day model 0	30-day model 1
C index	0.822 (0.796-0.848)	0.855 (0.830-0.879)
NRI (95%CI)		0.445 (0.339-0.523)
P value		<0.0001
IDI (95%CI)		0.040 (0.025-0.074)
P value		<0.0001
Likelihood ratio test (P value)		<0.0001
BIC	3434.091	3350.882

30-days Model 0: age, prior stroke, heart rate, Killip class, LVEF, and in-hospital PCI. 30-day Model 1: age, prior stroke, heart rate, Killip class, LVEF, in-hospital PCI, in-hospital recurrent myocardial ischemia, in-hospital recurrent myocardial infarction, in-hospital heart failure, antiplatelet therapy, and statins at discharge. LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; NRI, net reclassification index; CI, confidence interval; IDI, integrated discrimination improvement index; BIC, Bayesian information criteria.

Table 5. Comparison of 2-year prognostic models with or without adverse events and medications


	2-year model 0	2-year model 1
C index	0.822 (0.807-0.836)	0.825 (0.811-0.839)
NRI (95%CI)		0.119 (-0.045-0.176)
P value		0.126
IDI (95%CI)		0.008 (0.004-0.017)
P value		0.007
Likelihood ratio test (P value)		<0.0001
BIC	12792.602	12785.706

2-year Model 0: age, prior renal dysfunction, prior heart failure, AMI classification, heart rate, Killip class, hemoglobin, LVEF, in-hospital PCI, and in-hospital heart failure. 2-year Model 1: age, prior renal dysfunction, prior heart failure, AMI classification, heart rate, Killip class, hemoglobin, LVEF, in-hospital PCI, in-hospital heart failure, heart failure worsening within 30 days, antiplatelet therapy, β blockers, and statins within 30 days. AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; NRI, net reclassification index; CI, confidence interval; IDI, integrated discrimination improvement index; BIC, Bayesian information criteria.


1 2 3 1 **FIGURE LEGENDS** 4 5

6 2 **Figure 1. Nomogram for predicting 30-day survival probability.** The observed value of a
7
8 3 prognostic index was assigned a point by drawing a perpendicular line towards the top scale.
9
10 4 The sum of points for each index was plotted on the “Total points” scale, and corresponded to
11
12 5 the probability of 30-day survival at the bottom with a vertical line. LVEF, left ventricular
13
14 6 ejection fraction; PCI, percutaneous coronary intervention.
15
16
17

18 7
19
20
21 8 **Figure 2. Nomogram for predicting 2-year survival probability.** The observed value of a
22
23 9 prognostic index was assigned a point by drawing a perpendicular line towards the top scale.
24
25 10 The sum of points for each index was plotted on the “Total points” scale, and corresponded to
26
27 11 the probability of 2-year survival at the bottom with a vertical line. AMI, acute myocardial
28
29 12 infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.
30
31
32



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



Supplemental Materials

Junxing Lv et al. Dynamic risk prediction in patients following acute myocardial infarction.

I. Supplemental Tables.

Supplemental Table 1. Baseline characteristics, medications, and outcomes of cohorts for developing and validating 2-year prognostic model.

Supplemental Table 2. Univariable analysis of 30-day mortality.

Supplemental Table 3. Univariable analysis of mortality after 30 days.

Supplemental Table 4. Discrimination of 30-day prognostic nomogram in subgroups of patients.

Supplemental Table 5. Discrimination of 2-year prognostic nomogram in subgroups of patients.

II. Supplemental Figures.

Supplemental Figure 1. Flowchart of this study. AMI, acute myocardial infarction.

Supplemental Figure 2. Kaplan-Meier curve for patients after AMI hospitalization. AMI, acute myocardial infarction.

Supplemental Figure 3. Density plots for all-cause death and recurrent myocardial infarction during follow-up. (A) Density plot for all-cause death. (B) Density plot for recurrent myocardial infarction.

Supplemental Figure 4. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 1. (A) The plot showing partial likelihood deviance values versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute

shrinkage and selection operator; SE, standard error.

Supplemental Figure 5. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 2. (A) The plot showing partial likelihood deviance values versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute shrinkage and selection operator; SE, standard error.

Supplemental Figure 6. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 3. (A) The plot showing partial likelihood deviance values versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute shrinkage and selection operator; SE, standard error.

Supplemental Figure 7. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 4. (A) The plot showing partial likelihood deviance values versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute shrinkage and selection operator; SE, standard error.

Supplemental Figure 8. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 5. (A) The plot showing partial likelihood deviance values versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute shrinkage and selection operator; SE, standard error.

Supplemental Figure 9. Relative importance of selected predictors for 30-day mortality. Relative importance of variables selected by LASSO method was ranked according to the proportion of explainable log-likelihood ratio χ^2 statistics. LASSO, least absolute shrinkage and selection operator; Mi, myocardial ischemia; MI, myocardial infarction; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; HF, heart failure.

Supplemental Figure 10. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 1. (A) The plot showing partial likelihood deviance values

1
2
3 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
4 were drawn at values by the minimum criteria and the 1 SE of minimum criteria. The lambda
5 with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile
6 plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute shrinkage and
7 selection operator; SE, standard error.
8
9

10
11 **Supplemental Figure 11. Variable selection by LASSO method for 2-year prognostic**
12 **model in imputation dataset 2.** (A) The plot showing partial likelihood deviance values
13 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
14 were drawn at values by the minimum criteria and the 1 SE of minimum criteria. The lambda
15 with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile
16 plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute shrinkage and
17 selection operator; SE, standard error.
18
19

20
21
22 **Supplemental Figure 12. Variable selection by LASSO method for 2-year prognostic**
23 **model in imputation dataset 3.** (A) The plot showing partial likelihood deviance values
24 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
25 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
26 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
27 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
28 shrinkage and selection operator; SE, standard error.
29
30

31
32
33 **Supplemental Figure 13. Variable selection by LASSO method for 2-year prognostic**
34 **model in imputation dataset 4.** (A) The plot showing partial likelihood deviance values
35 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
36 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
37 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
38 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
39 shrinkage and selection operator; SE, standard error.
40
41

42
43
44 **Supplemental Figure 14. Variable selection by LASSO method for 2-year prognostic**
45 **model in imputation dataset 5.** (A) The plot showing partial likelihood deviance values
46 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
47 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
48 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
49 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
50 shrinkage and selection operator; SE, standard error.
51
52

53
54
55 **Supplemental Figure 15. Relative importance of selected predictors for 2-year mortality.**
56 Relative importance of variables selected by LASSO method was ranked according to the
57 proportion of explainable log-likelihood ratio χ^2 statistics. LASSO, least absolute shrinkage
58 and selection operator; HF, heart failure; AMI, acute myocardial infarction; LVEF, left
59 ventricular ejection fraction; PCI, percutaneous coronary intervention.
60

1
2
3
4
5 **Supplemental Figure 16. Comparisons of clinical utilities between models with or**
6 **without adverse events and medications.** The red and green lines represent the assumption
7 that all or none patients at high risk with different thresholds. The lines in the upper right
8 represent the risk prediction models. (A) Comparison of clinical utilities between 30-day
9 model with or without adverse events and medications. (B) Comparison of clinical utilities
10 between 2-year model with or without adverse events and medications.
11
12
13
14
15

16 **Supplemental Figure 17. Comparisons of clinical utilities between models and GRACE**
17 **risk score.** The red and green lines represent the assumption that all or none patients at high
18 risk with different thresholds. The lines in the upper right represent the risk prediction models.
19 (A) Comparison of clinical utilities between 30-day model and GRACE risk score. (B)
20 Comparison of clinical utilities between 2-year model and GRACE risk score. GRACE,
21 Global Registry of Acute Coronary Events.
22
23
24
25
26

27 **Supplemental Figure 18. Calibration curves of 30-day prognostic nomogram.** Calibration
28 curves present the relationship between observed and predicted survival probabilities by 30-
29 day prognostic nomogram in both derivation and validation cohorts. (A) Calibration curve of
30 30-day prognostic nomogram in derivation cohort. (B) Calibration curve of 30-day prognostic
31 nomogram in validation cohort.
32
33
34
35

36 **Supplemental Figure 19. Calibration curves of 2-year prognostic nomogram.** Calibration
37 curves present the relationship between observed and predicted survival probabilities by 2-
38 year prognostic nomogram in both derivation and validation cohorts. (A) Calibration curve of
39 2-year prognostic nomogram in derivation cohort. (B) Calibration curve of 2-year prognostic
40 nomogram in validation cohort.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

I. Supplemental Tables.

Supplemental Table 1. Baseline characteristics, medications, and outcomes of cohorts for developing and validating 2-year prognostic model

Variables	Derivation cohort (n=12136)	Validation cohort (n=6067)	P value
Demographics			
Age, yrs	62.08±12.28	62.26±12.20	0.3634
Female	2967 (24.4)	1459 (24.0)	0.5531
BMI, kg/m ²	24.12±3.02	24.11±3.01	0.8755
Medical history			
Diabetes	2213 (19.0)	1146 (19.6)	0.2974
Hypertension	6021 (50.6)	3011 (50.7)	0.8935
Hyperlipidemia	760 (7.2)	382 (7.2)	0.9871
Current smoker	5565 (46.3)	2737 (45.5)	0.3511
Prior angina pectoris	3173 (28.0)	1571 (27.8)	0.7999
Prior myocardial infarction	821 (7.2)	420 (7.3)	0.6981
Prior heart failure	243 (2.1)	120 (2.1)	0.9227
Prior stroke	1038 (8.8)	572 (9.7)	0.0503
Prior peripheral artery disease	72 (0.6)	30 (0.5)	0.3967
Prior PCI	562 (4.8)	293 (5.0)	0.5356
Prior CABG	38 (0.3)	25 (0.4)	0.2883
Prior renal dysfunction	130 (1.1)	56 (1.0)	0.3474
COPD	221 (1.9)	114 (2.0)	0.7794
Presenting characteristics			
Symptom onset to admission time			0.1659
0-6h	5725 (47.6)	2798 (46.5)	
>6h	6298 (52.4)	3216 (53.5)	
Heart rate, beats/min	77.37±18.06	77.63±18.04	0.3710
Systolic blood pressure	129.61±25.30	130.00±25.52	0.3250
Killip class			0.8824
I	9163 (76.2)	4589 (76.3)	
II-IV	2859 (23.8)	1424 (23.7)	
Cardiac arrest at admission	95 (0.8)	62 (1.0)	0.1055

1				
2				
3	AMI classification			0.2540
4				
5	STEMI	9215 (75.9)	4560 (75.2)	
6				
7	NSTEMI	2921 (24.1)	1507 (24.8)	
8				
9	Anterior wall involvement	5743 (47.7)	2843 (47.2)	0.5888
10	Laboratory results			
11				
12	Creatinine, $\mu\text{mol/L}$	74.00 (61.80, 89.10)	73.90 (61.40, 89.60)	0.7455
13				
14	Creatinine clearance, ml/min	84.53 (62.60, 109.58)	84.92 (63.22, 110.16)	0.9369
15				
16	Hemoglobin, g/L	136.37 \pm 20.82	136.39 \pm 20.79	0.9582
17				
18	Leukocyte count, $\times 10^9/\text{L}$	10.09 \pm 3.65	10.02 \pm 3.52	0.1737
19				
20	LVEF, %	54.08 \pm 10.00	54.01 \pm 9.94	0.7200
21	In-hospital treatment			
22				
23	In-hospital PCI	6998 (58.4)	3468 (57.7)	0.4281
24				
25	In-hospital CABG	87 (0.7)	50 (0.8)	0.4388
26				
27	Adverse events during hospitalization			
28				
29	New-onset heart failure	1616 (13.5)	805 (13.5)	0.9477
30				
31	Recurrent myocardial ischemia	281 (2.3)	125 (2.1)	0.2736
32				
33	Recurrent myocardial infarction	37 (0.3)	18 (0.3)	0.9259
34				
35	Stroke	65 (0.5)	29 (0.5)	0.6109
36				
37	Other bleeding events	183 (1.5)	94 (1.6)	0.8199
38	Medications within 30 days			
39				
40	Antiplatelet therapy			0.4345
41				
42	Dual antiplatelet therapy	10518 (86.7)	5287 (87.1)	
43				
44	Single antiplatelet therapy	1292 (10.6)	610 (10.1)	
45				
46	None	326 (2.7)	170 (2.8)	
47				
48	Statins	11486 (94.6)	5736 (94.5)	0.7789
49				
50	β blockers	8751 (72.1)	4347 (71.6)	0.5171
51				
52	ACEI/ARB	7221 (59.5)	3591 (59.2)	0.6866

Values are shown as mean \pm standard deviation, median (interquartile range), or number (%) without imputation of missing data. BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II

1
2
3 receptor blocker.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplemental Table 2. Univariable analysis of 30-day mortality

	Unadjusted HR (95% CI)	P value
Age (per 1 year increase)	1.066 (1.052, 1.080)	<0.0001
Women (vs men)	1.662 (1.233, 2.241)	0.0009
BMI (per 1kg/m ² increase)	0.893 (0.850, 0.939)	<0.0001
Diabetes (vs no)	1.545 (1.123, 2.126)	0.0075
Hypertension (vs no)	1.289 (0.958, 1.734)	0.0930
Hyperlipidemia (vs no)	0.749 (0.406, 1.384)	0.3547
Current smoking (vs no)	0.406 (0.293, 0.563)	<0.0001
Prior angina pectoris (vs no)	1.324 (0.972, 1.803)	0.0754
Prior myocardial infarction (vs no)	1.177 (0.709, 1.954)	0.5284
Prior heart failure (vs no)	5.078 (3.166, 8.144)	<0.0001
Prior stroke (vs no)	2.627 (1.842, 3.747)	<0.0001
Prior PCI (vs no)	0.814 (0.400, 1.659)	0.5717
Prior CABG (vs no)	—	—
Prior renal dysfunction (vs no)	1.596 (0.587, 4.338)	0.3591
COPD (vs no)	3.208 (1.744, 5.901)	0.0002
Prior peripheral artery disease (vs no)	—	—
Symptom onset to admission time (vs 0-6h)		
>6h	1.947 (1.431, 2.649)	<0.0001
Heart rate (per 1 beat increase)	1.024 (1.018, 1.029)	<0.0001
Systolic blood pressure (per 1mmHg increase)	0.994 (0.988, 1.000)	0.0358
Killip class (vs I)		
II-IV	3.980 (2.990, 5.298)	<0.0001
Cardiac arrest at admission (vs no)	1.921 (0.614, 6.011)	0.2620
NSTEMI (vs STEMI)	1.230 (0.898, 1.686)	0.1977
Anterior wall involvement (vs no)	1.255 (0.943, 1.671)	0.1185
Creatinine clearance (vs >90 ml/min)		
60-90	1.805 (1.222, 2.666)	0.0030
≤60	4.252 (2.985, 6.058)	<0.0001
Hemoglobin (per 1g/L increase)	0.988 (0.983, 0.993)	<0.0001
Leukocyte count (per 10 ⁹ /L increase)	1.055 (1.023, 1.088)	0.0006

1			
2			
3	LVEF (per 1% increase)	0.938 (0.923, 0.952)	<0.0001
4			
5	In-hospital PCI (vs no)	0.220 (0.157, 0.308)	<0.0001
6			
7	In-hospital CABG (vs no)	1.277 (0.317, 5.145)	0.7308
8			
9	New-onset heart failure during hospitalization (vs no)	7.204 (5.414, 9.585)	<0.0001
10			
11	Recurrent myocardial ischemia during hospitalization (vs no)	6.028 (3.938, 9.228)	<0.0001
12			
13	Recurrent myocardial infarction during hospitalization (vs no)	13.299 (6.752, 26.195)	<0.0001
14			
15			
16	Stroke during hospitalization (vs no)	2.908 (0.934, 9.052)	0.0654
17			
18	Other bleeding events during hospitalization (vs no)	4.109 (2.235, 7.558)	<0.0001
19			
20	Antiplatelet therapy at discharge (vs dual therapy)		
21			
22	Single antiplatelet therapy	1.344 (0.762, 2.372)	0.3024
23			
24	none	5.158 (3.468, 7.672)	<0.0001
25			
26	Statins at discharge (vs no)	3.180 (2.246, 4.502)	<0.0001
27			
28	β blockers at discharge (vs no)	1.483 (1.105, 1.991)	0.0087
29			
30	ACEI/ARB at discharge (vs no)	1.481 (1.088, 2.017)	0.0128

BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HR, hazard ratio; CI, confidence interval.

Supplemental Table 3. Univariable analysis of mortality after 30 days

	Unadjusted HR (95% CI)	P value
Age (per 1 year increase)	1.084 (1.076, 1.092)	<0.0001
Women (vs men)	1.947 (1.679, 2.259)	<0.0001
BMI (per 1kg/m ² increase)	0.895 (0.872, 0.919)	<0.0001
Diabetes (vs no)	1.571 (1.328, 1.857)	<0.0001
Hypertension (vs no)	1.533 (1.321, 1.779)	<0.0001
Hyperlipidemia (vs no)	0.631 (0.443, 0.900)	0.0111
Current smoking (vs no)	0.423 (0.359, 0.498)	<0.0001
Prior angina pectoris (vs no)	1.318 (1.131, 1.536)	0.0004
Prior myocardial infarction (vs no)	2.064 (1.657, 2.570)	<0.0001
Prior heart failure (vs no)	5.964 (4.685, 7.594)	<0.0001
Prior stroke (vs no)	2.013 (1.651, 2.455)	<0.0001
Prior PCI (vs no)	1.122 (0.817, 1.540)	0.4770
Prior CABG (vs no)	1.656 (0.618, 4.433)	0.3156
Prior renal dysfunction (vs no)	4.383 (2.969, 6.470)	<0.0001
COPD (vs no)	2.897 (2.076, 4.044)	<0.0001
Prior peripheral artery disease (vs no)	2.273 (1.197, 4.314)	0.0122
Symptom onset to admission time (vs 0-6h)		
>6h	1.497 (1.287, 1.742)	<0.0001
Heart rate (per 1 beat increase)	1.021 (1.018, 1.024)	<0.0001
Systolic blood pressure (per 1mmHg increase)	1.005 (1.002, 1.008)	0.0005
Killip class (vs I)		
II-IV	3.225 (2.792, 3.726)	<0.0001
Cardiac arrest at admission (vs no)	1.068 (0.478, 2.388)	0.8724
NSTEMI (vs STEMI)	2.395 (2.070, 2.771)	<0.0001
Anterior wall involvement (vs no)	1.210 (1.047, 1.398)	0.0096
Creatinine clearance (vs >90 ml/min)		
60-90	1.725 (1.405, 2.119)	<0.0001
≤60	5.193 (4.328, 6.231)	<0.0001
Hemoglobin (per 1g/L increase)	0.980 (0.978, 0.983)	<0.0001
Leukocyte count (per 10 ⁹ /L increase)	1.010 (0.990, 1.030)	0.3333

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

LVEF (per 1% increase)	0.948 (0.941, 0.955)	<0.0001
In-hospital PCI (vs no)	0.207 (0.175, 0.246)	<0.0001
In-hospital CABG (vs no)	0.421 (0.106, 1.674)	0.2184
New-onset heart failure during hospitalization (vs no)	3.418 (2.932, 3.984)	<0.0001
Recurrent myocardial ischemia during hospitalization (vs no)	2.653 (1.949, 3.610)	<0.0001
Recurrent myocardial infarction during hospitalization (vs no)	1.773 (0.659, 4.771)	0.2565
Stroke during hospitalization (vs no)	3.455 (1.991, 5.996)	<0.0001
Other bleeding events during hospitalization (vs no)	2.233 (1.486, 3.356)	0.0001
Recurrent myocardial infarction within 30 days (vs no)	3.032 (1.130-8.134)	0.0276
Heart failure worsening within 30 days (vs no)	4.790 (3.631, 6.319)	<0.001
Antiplatelet therapy within 30 days (vs dual antiplatelet therapy)		
Single antiplatelet therapy	2.147 (1.779, 2.591)	<0.0001
none	4.371 (3.385, 5.643)	<0.0001
Statins within 30 days (vs no)	2.454 (1.960, 3.073)	<0.0001
β blockers within 30 days (vs no)	1.594 (1.374, 1.850)	<0.0001
ACEI/ARB within 30 days (vs no)	1.153 (0.997, 1.333)	0.0546

BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HR, hazard ratio; CI, confidence interval.

Supplemental Table 4. Discrimination of 30-day prognostic nomogram in subgroups of patients

Subgroup	Sample size	C statistic (95% CI)
Age, yrs		
≤75	4766	0.74 (0.65-0.84)
>75	935	0.83 (0.71-0.94)
Sex		
Male	4359	0.79 (0.69-0.88)
Female	1342	0.75 (0.62-0.88)
Diabetes		
Yes	1106	0.81 (0.62-1.00)
No	4431	0.78 (0.70-0.87)
Diagnosis		
STEMI	4302	0.77 (0.68-0.86)
NSTEMI	1399	0.83 (0.72-0.93)
In-hospital PCI		
Yes	3498	0.76 (0.63-0.88)
No	2203	0.76 (0.66-0.85)

STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CI, confidence interval.


Supplemental Table 5. Discrimination of 2-year prognostic nomogram in subgroups of patients

Subgroup	Sample size	C statistic (95% CI)
Age, yrs		
≤75	3766	0.79 (0.75-0.83)
>75	695	0.66 (0.62-0.71)
Sex		
Male	3412	0.83 (0.80-0.86)
Female	1049	0.75 (0.70-0.80)
Diabetes		
Yes	845	0.81 (0.76-0.86)
No	3496	0.81 (0.78-0.84)
AMI classification		
STEMI	3364	0.81 (0.78-0.84)
NSTEMI	1097	0.81 (0.76-0.85)
In-hospital PCI		
Yes	3104	0.82 (0.78-0.87)
No	1357	0.72 (0.68-0.76)

AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CI, confidence interval.


II. Supplemental Figures.

Supplemental Figure 1. Flowchart of this study




review only

Supplemental Figure 2. Kaplan-Meier curve for patients after AMI hospitalization




Peer review only

Supplemental Figure 3. Density plots for all-cause death and recurrent myocardial infarction during follow-up




Supplemental Figure 4. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 1


A




B





Supplemental Figure 5. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 2




Supplemental Figure 6. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 3




Supplemental Figure 7. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 4



Supplemental Figure 8. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 5




1
2
3 **Supplemental Figure 9. Relative importance of selected predictors for 30-day mortality**
4
5
6
7
8
9




Supplemental Figure 10. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 1

A




B




Supplemental Figure 11. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 2

A




B




Supplemental Figure 12. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 3


A



B




Supplemental Figure 13. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 4




Supplemental Figure 14. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 5


A





B





1
2
3 **Supplemental Figure 15. Relative importance of selected predictors for 2-year mortality**
4
5
6
7
8
9



Supplemental Figure 16. Comparisons of clinical utilities between models with or without adverse events and medications




Supplemental Figure 17. Comparisons of clinical utilities between models and GRACE risk score




Supplemental Figure 18. Calibration curves of 30-day prognostic nomogram

A




B




Supplemental Figure 19. Calibration curves of 2-year prognostic nomogram

A



B



TRIPOD Checklist: Prediction Model Development

Section	Item	Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract				
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.		
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.		
Introduction				
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.		
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.		
Methods				
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.		
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.		
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.		
	5b	Describe eligibility criteria for participants.		
	5c	Give details of treatments received, if relevant.		
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.		
	6b	Report any actions to blind assessment of the outcome to be predicted.		
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.		
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.		
Sample size	8	Explain how the study size was arrived at.		

Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.		
Statistical analysis methods	10a	Describe how predictors were handled in the analyses.		
	10b	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.		
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.		
Risk groups	11	Provide details on how risk groups were created, if done.		
Results				
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.		
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.		
Model development	14a	Specify the number of participants and outcome events in each analysis.		
	14b	If done, report the unadjusted association between each candidate predictor and outcome.		
Model specification	15a	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).		
	15b	Explain how to use the prediction model.		
Model performance	16	Report performance measures (with CIs) for the prediction model.		
Discussion				
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).		
Interpretation	19b	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.		
Implications	20	Discuss the potential clinical use of the model and implications for future research.		
Other information				
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.		
Funding	22	Give the source of funding and the role of the funders for the present study.		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



For peer review only

BMJ Open

Development and validation of dynamic models to predict post-discharge mortality risk in patients with acute myocardial infarction: results from China Acute Myocardial Infarction registry

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069505.R1
Article Type:	Original research
Date Submitted by the Author:	16-Feb-2023
Complete List of Authors:	<p>Lv, Junxing; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>Wang, Chuang-Shi; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 102300, China.</p> <p>Gao, Xiaojin; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>Yang, Jingang; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>Zhang, Xuan; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>Ye, Yunqing; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Department of Cardiology</p> <p>Dong, Qiuting; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Department of Cardiology</p> <p>Fu, Rui; Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>sun, hui; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Cardiology</p> <p>Yan, Xinxin; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Department of Cardiology</p> <p>Zhao, Yanyan; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Medical Research & Biometrics Center</p> <p>Yang, Wang; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital</p> <p>Xu, Haiyan; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Department of Cardiology</p> <p>Yang, Yuejin; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Myocardial infarction < CARDIOLOGY, Coronary heart disease <

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	CARDIOLOGY, Coronary intervention < CARDIOLOGY, Prognosis

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Development and validation of dynamic models to predict post-discharge**
4
5
6 2 **mortality risk in patients with acute myocardial infarction: results from**
7
8
9 3 **China Acute Myocardial Infarction registry**

10
11
12 4 **Running title:** Dynamic models in patients with AMI
13
14
15 5

16
17
18 6 Junxing Lv, MD^{1,*}, Chuangshi Wang, PhD^{2,*}, Xiaojin Gao, MD, PhD¹, Jingang Yang, MD,
19
20 7 PhD¹, Xuan Zhang, MD¹, Yunqing Ye, MD¹, Qiuting Dong, MD, PhD¹, Rui Fu, MD¹, Hui Sun,
21
22 8 MD¹, Xinxin Yan, MD, PhD¹, Yanyan Zhao, PhD², Yang Wang, PhD², Haiyan Xu, MD, PhD^{1,†},
23
24
25 9 and Yuejin Yang, MD, PhD^{1,†}; on behalf of the China Acute Myocardial Infarction Registry
26
27
28 10 study group
29
30
31 11

32
33
34 12 ¹ Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases,
35
36 13 Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

37
38 14 ² Medical Research & Biometrics Center, Fuwai Hospital, National Center for Cardiovascular
39
40
41 15 Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,
42
43 16 China
44
45
46 17

47
48
49 18 * Junxing Lv and Chuangshi Wang contributed equally to this work as joint first authors.

50
51
52 19 † Haiyan Xu and Yuejin Yang contributed equally to this work as joint corresponding authors.
53
54
55 20

56
57
58 21 **Correspondence:**
59
60

1
2
3 1 Haiyan Xu
4
5

6 2 Address: No. 167 Beilishi Road, Xicheng District, 100037, Beijing, China.
7
8

9 3 Tel: +86-10-88396082 Fax: +86-10-88396237
10
11

12 4 E-mail: xuhaiyan@fuwaihospital.org
13
14

15 5 Yuejin Yang
16
17

18 6 Address: No. 167 Beilishi Road, Xicheng District, 100037, Beijing, China.
19
20

21 7 E-mail: yangyjfw@126.com
22
23

24 8
25

26
27 9 **Word count**
28

29
30 10 **Abstract: 299 Main text (not including references, tables, and figure legends): 3775**
31
32

33 11
34
35

36 12
37
38

39 13
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The risk of adverse events and prognostic factors are changing in different time phases after acute myocardial infarction (AMI). The incidence of adverse events is considerable in the early period after AMI hospitalization. Therefore, dynamic risk prediction is needed to guide post-discharge management of AMI. This study aimed to develop a dynamic risk prediction instrument for patients following AMI.

Design: A retrospective analysis of a prospective cohort.

Setting: 108 hospitals in China.

Participants: A total of 23887 patients after AMI in the China Acute Myocardial Infarction registry were included in this analysis.

Primary outcome measures: All-cause mortality.

Results: In multivariable analyses, age, prior stroke, heart rate, Killip class, left ventricular ejection fraction (LVEF), in-hospital percutaneous coronary intervention (PCI), recurrent myocardial ischemia, recurrent myocardial infarction, heart failure (HF) during hospitalization, antiplatelet therapy, and statins at discharge were independently associated with 30-day mortality. Variables related to mortality between 30 days and 2 years included age, prior renal dysfunction, history of HF, AMI classification, heart rate, Killip class, hemoglobin, LVEF, in-hospital PCI, HF during hospitalization, HF worsening within 30 days after discharge, antiplatelet therapy, β blocker, and statins use within 30 days after discharge. The inclusion of adverse events and medications significantly improved the predictive performance of models without these indexes (likelihood ratio test $P < 0.0001$). These two sets of predictors were used to establish dynamic prognostic nomograms for predicting mortality in patients with AMI. The C indexes of 30-day and 2-year prognostic nomograms were 0.85 (95% confidence interval

1
2
3 1 [CI]: 0.83-0.88) and 0.83 (95% CI: 0.81-0.84) in derivation cohort, and 0.79 (95% CI: 0.71-
4
5 2 0.86) and 0.81 (95% CI: 0.79-0.84) in validation cohort, with satisfying calibration.
6
7

8 3 **Conclusions:** We established dynamic risk prediction models incorporating adverse event and
9
10 4 medications. The nomograms may be useful instruments to help prospective risk assessment
11
12 and management of AMI.
13 5
14

15
16 6 **Trial registration number:** NCT01874691.
17
18

19 7
20
21
22 8 **Keywords:** Myocardial infarction, risk prediction, model, prognosis
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- We developed and validated a dynamic risk prediction tool using data from a large, prospective, multicenter registry.
- We analyzed the incremental prognostic value of in-hospital and post-discharge adverse events as well as medications over traditional predictors in patients following acute myocardial infarction.
- We compared the predictive performance of our models with existing risk prediction tools, including the Global Registry of Acute Coronary Events 1.0 and 2.0 scores.
- The predictive performance of the dynamic risk prediction tool can be further improved if including more follow-up information.
- The dynamic risk prediction tool should be further validated in external cohorts.

1 2 3 1 **Introduction** 4 5

6 2 Although in-hospital mortality of acute myocardial infarction (AMI) has been decreased in
7
8 3 many countries,^[1,2] risk of adverse events remains considerable in survivors after AMI
9
10 4 hospitalization.^[3] Previous studies have indicated unsatisfying and imbalanced quality of
11
12 5 secondary prevention medications in clinical practice,^[4,5] which can cause negative impact on
13
14 6 prognosis of AMI patients. Individualized risk assessment may aid in decision making of long-
15
16 7 term therapeutic strategies for patients after AMI. However, the existing risk prediction tools,
17
18 8 which are mainly based on predictive indexes collected at admission, fail to consider the
19
20 9 changing nature of adverse events and medications after AMI hospitalization,^[6,7] and therefore
21
22 10 may not be appropriate to guide long-term management. Dynamic risk assessment may help
23
24 11 improve the quality of long-term management for patients following AMI.
25
26
27
28
29

30 12 Although several studies sought to forecast mortality dynamically in patients with acute
31
32 13 coronary syndromes,^[8-11] the prognostic components of these models were obtained during
33
34 14 hospitalization, without taking follow-up adverse events and medications into consideration.
35
36 15 Dynamic prognostic instruments designed to help risk reassessment should include post-
37
38 16 discharge information which is associated with outcomes. In this study, we aimed to develop
39
40 17 and validate dynamic risk prediction models, visualized by nomograms, which included in-
41
42 18 hospital and post-discharge adverse events and medications, to assist in prognostic evaluation
43
44 19 and decision-making of secondary prevention strategies in patients following AMI.
45
46
47
48
49
50

51 21 **Methods** 52 53

54 22 *Study population* 55 56

57 23 The data for the present study were from the China Acute Myocardial Infarction (CAMI)
58
59 24 registry. The design of the CAMI registry has been described and published elsewhere.^[12]
60

1
2
3 1 Briefly, 108 hospitals from 31 provinces and municipalities throughout Mainland China were
4
5 2 included in this prospective, nationwide, multicenter registry. Consecutive patients with AMI
6
7 3 were enrolled in the registry and the final diagnosis of patients must meet the third Universal
8
9 4 Definition for Myocardial Infarction (2012).^[13] All types of AMI were eligible for the CAMI
10
11 5 registry, except type 4a and type 5. Presenting characteristics, medical history, laboratory
12
13 6 results, medications, and clinical outcomes were collected according to the American College
14
15 7 of Cardiology/American Heart Association Task Force on clinical data standards and NCDR-
16
17 8 ACTION-GWTG element dictionary.
18
19
20
21

22 9 Patients registered in the CAMI registry from January 2013 to September 2014 were
23
24 10 included in this study. Those with invalid diagnosis (n=1312), who were transferred out
25
26 11 (n=1181) or died during hospitalization (n=1690) were excluded. The remaining population
27
28 12 (n=23887) was divided randomly according to 2:1 ratio into derivation (n=15925) and
29
30 13 validation (n=7962) cohorts for developing and validating a 30-day risk prediction model. After
31
32 14 further excluding patients who died within 30 days after discharge (n=293) and those with
33
34 15 missing data on 30-day medication use (n=5391), the remaining derivation (n=12136) and
35
36 16 validation (n=6067) cohorts were used for establishing and testing a 2-year risk prediction
37
38 17 model (online supplemental figure 1).
39
40
41
42
43
44 18
45

46 19 ***Definitions***

47
48
49 20 Standard definitions of adverse events have been described elsewhere in detail.^[14] Taking a
50
51 21 medication within 30 days means using the medication during this period after discharge
52
53 22 without discontinuation.
54
55
56
57 23
58
59
60 24

60 24 ***Follow-up and endpoints***

1
2
3 1 Patients were followed by clinical visits or telephone call at 30 days, 6 months, 12 months, 18
4
5 2 months, and 24 months. Adverse events (such as death, recurrent myocardial infarction, and
6
7 3 heart failure worsening) and medications at follow-up time points were collected by trained
8
9 4 cardiologists or cardiovascular fellows. The primary endpoints of this analysis were all-cause
10
11 5 mortality within 30 days after AMI hospitalization (for establishing 30-day risk prediction
12
13 6 model) and mortality between 30 days and 2 years (for establishing 2-year risk prediction
14
15 7 model).

21 8

22

23 9 ***Statistical analysis***

24

25

26 10 Categorical variables were summarized as frequencies and percentages, and compared by chi-
27
28 11 square or Fisher exact test, as appropriate. Continuous variables were expressed as mean \pm
29
30 12 standard deviation or medians (interquartile range) according to data distributions, and
31
32 13 compared by student t or nonparametric test. Kaplan-Meier curve and density plots were used
33
34 14 to depict the changing nature of risk after AMI hospitalization. In the derivation cohort, 190
35
36 15 deaths occurred within 30 days after discharge, which could ensure at most 19 predictor
37
38 16 parameters (greater than 12 predictor parameters finally included) in the 30-day risk prediction
39
40 17 model based on the rule of thumb that 10 events per candidate predictor parameters (EPP).
41
42 18 Similarly, 740 deaths occurred between 30 days and 2 years, which could ensure at most 74
43
44 19 predictor parameters (greater than 15 predictor parameters finally included) in the 2-year risk
45
46 20 prediction model.^[15]

47
48
49
50
51 21 The derivation cohort was used to identify predictors of 30-day mortality and mortality
52
53 22 between 30 days and 2 years. The associations between variables, including age, sex, body mass
54
55 23 index (BMI), diabetes, hypertension, hyperlipidemia, smoking, prior angina pectoris, prior
56
57 24 myocardial infarction, prior heart failure, prior stroke, prior peripheral artery disease, prior
58
59
60

1
2
3 1 percutaneous coronary intervention (PCI), prior coronary artery bypass graft (CABG), prior
4
5 2 renal dysfunction, chronic obstructive pulmonary disease (COPD), symptom onset to admission
6
7
8 3 time, heart rate, systolic blood pressure, Killip class, cardiac arrest at admission, diagnosis,
9
10 4 anterior wall involvement, creatinine clearance, hemoglobin, leukocyte count, left ventricular
11
12 5 ejection fraction (LVEF), in-hospital PCI, in-hospital CABG, heart failure, recurrent
13
14 6 myocardial ischemia, recurrent myocardial infarction, stroke, other bleeding events (bleeding
15
16 7 events not including cerebral hemorrhage) during hospitalization, antiplatelet therapy at
17
18 8 discharge, statins at discharge, β blockers at discharge, and angiotensin converting enzyme
19
20 9 inhibitor (ACEI) or angiotensin II receptor blocker (ARB) at discharge, and 30-day mortality
21
22 10 were first assessed in univariable Cox regression models. For obtaining prognostic factors of
23
24 11 mortality between 30 days and 2 years, the associations of adverse events within 30 days
25
26 12 (recurrent myocardial infarction and heart failure worsening) and 30-day medications
27
28 13 (antiplatelet therapy, statins, β blockers, and ACEI/ARB) with mortality were also assessed in
29
30 14 univariable Cox models besides variables mentioned previously. Subsequently, the least
31
32 15 absolute shrinkage and selection operator (LASSO) method was adopted to select predictors of
33
34 16 short-term and long-term mortality respectively from variables with $P \leq 0.1$ in univariable
35
36 17 analysis. The selected predictors were used to establish dynamic risk prediction models by
37
38 18 multivariable Cox regression model. The relative importance of these variables was ranked
39
40 19 according to the proportion of explainable log-likelihood ratio χ^2 statistics.

41
42 20 To analyze the incremental prognostic value of adverse events and medications over
43
44 21 traditional predictive indexes, we compared the predictive performance between models with
45
46 22 or without adverse events and medications using C index, net reclassification index (NRI),
47
48 23 integrated discrimination improvement index (IDI), likelihood ratio test, and Bayesian
49
50 24 information criteria (BIC). The clinical utility of models were compared by decision curve
51
52 25 analysis. Predictive performance was also compared between 30-day risk model or 2-year risk
53
54
55
56
57
58
59
60

1
2
3 1 model and the Global Registry of Acute Coronary Events (GRACE) risk scores (version 1.0
4
5 2 and 2.0) to further analyze the additional value of the dynamic models beyond existing
6
7
8 3 prognostic tool.^[6,16]
9

10
11 4 Two prognostic nomograms, which could make complex predictive formulas friendly to
12
13 5 use in clinical practice, were constructed based on the regression coefficients of predictors for
14
15 6 mortality using the “rms” package of R software. Discrimination and calibration of the
16
17 7 nomograms were assessed by C index and calibration curves presenting the relationship
18
19 8 between observed and predicted survival probabilities in both derivation and validation cohorts.
20
21 9 Subgroup analyses were performed in patients with complete data on model predictors in the
22
23 10 validation cohort according to age, sex, diabetes, AMI classification, in-hospital PCI, and
24
25 11 hospital level (province level, prefecture level, and county level).
26
27
28
29

30 12 Before regression analysis, we used Martingale residual plots to check the linearity
31
32 13 assumption for continuous variables (online supplemental figure 2 and 3). We also calculated
33
34 14 variance inflation factor to examine multicollinearity issue. The proportional hazards
35
36 15 assumptions were tested by inspection of Schoenfeld residual plots (online supplemental figure
37
38 16 4 and 5). Multiple imputation was used to generate 5 datasets without missing values. The
39
40 17 LASSO method was performed in each dataset. Only variables selected by LASSO method in
41
42 18 all 5 datasets were included in final dynamic risk prediction models. Number of missing values
43
44 19 for selected predictors were shown in online supplemental table 1. Results of Cox regression
45
46 20 models were reported as hazard ratios (HR) with 95% confidence intervals (CI). A two-tailed
47
48 21 $P < 0.05$ was considered statistically significant. Statistical analyses were performed using R
49
50 22 version 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria) and SAS version 9.4
51
52 23 (SAS Institute Inc., Cary, NC, USA).
53
54
55
56
57
58
59
60

Patient and public involvement

Patients or the public were not involved directly in the design, conduct, reporting or dissemination plans of our research.

Results

Baseline characteristics, medications, and outcomes of derivation and validation cohorts were summarized in table 1, online supplemental table 2 and online supplemental table 3. Rates of 30-day mortality among hospital survivors in derivation and validation cohorts were 1.2% (190/15925 patients) and 1.3% (103/7962 patients), respectively. Rates of mortality between 30 days and 2 years were 6.1% (740/12136 patients) and 5.7% (345/6067 patients). The Kaplan-Meier curve and density plots showed the changing risk of death and recurrent myocardial infarction within 2 years after AMI hospitalization (online supplemental figure 6 and 7).

Predictors of 30-day mortality in patients after AMI

Univariable analysis of the associations between variables and 30-day mortality was presented in online supplemental table 4. In the LASSO-based Cox regression model, age, prior stroke, heart rate, Killip class, LVEF, in-hospital PCI, in-hospital recurrent myocardial ischemia, in-hospital recurrent myocardial infarction, in-hospital heart failure, antiplatelet therapy, and statins at discharge were independently associated with 30-day mortality (online supplemental figure 8 to 12; table 2). The relative importance of these predictors was ranked and shown in online supplemental figure 13.

Predictors of 2-year mortality for 30-day survivors after AMI hospitalization

1
2
3 1 Univariable analysis of mortality between 30 days and 2 years after AMI hospitalization was
4
5 2 shown in online supplemental table 5. In the LASSO-based Cox regression model, age, prior
6
7 3 renal dysfunction, history of heart failure, AMI classification, heart rate, Killip class,
8
9 4 hemoglobin, LVEF, in-hospital PCI, in-hospital heart failure, heart failure worsening within 30
10
11 5 days, antiplatelet therapy, β blocker, and statins within 30 days were identified as predictors of
12
13 6 mortality (online supplemental figure 14 to 18; table 3). The relative importance of these
14
15 7 predictors was ranked and presented in online supplemental figure 19.
16
17
18
19
20 8

21 22 23 9 ***Incremental prognostic value of adverse events and medications***

24
25
26 10 The inclusion of in-hospital recurrent myocardial ischemia, in-hospital recurrent myocardial
27
28 11 infarction, in-hospital heart failure, antiplatelet therapy, and statins at discharge significantly
29
30 12 improved the predictive power of 30-day risk prediction model (table 4; 30-day model 1 vs 30-
31
32 13 day model 0: C index, 0.855 [0.830-0.879] vs 0.822 [0.796-0.848]; NRI [95%CI], 0.445 [0.339-
33
34 14 0.523], $P<0.0001$; IDI [95%CI], 0.040 [0.025-0.074], $P<0.0001$; likelihood ratio test $P<0.0001$;
35
36 15 BIC, 3434.091 vs 3350.882). In the 2-year risk prediction model, heart failure worsening within
37
38 16 30 days, antiplatelet, β blocker, and statins within 30 days also provided additional prognostic
39
40 17 value over predictive indexes obtained during hospitalization (table 5). The decision curve
41
42 18 analysis further demonstrated better clinical utility after adding adverse events and medications
43
44 19 into 30-day and 2-year risk models (online supplemental figure 20). Notably, the hospital level
45
46 20 provided no incremental value to 30-day or 2-year risk models (the inclusion of hospital level
47
48 21 to 30-day model, likelihood ratio test $P=0.4174$; to 2-year model, likelihood ratio test $P=0.5621$;
49
50 22 online supplemental figure 21).
51
52
53
54
55
56
57
58
59
60

23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ***Comparisons of prognostic models and GRACE risk scores***

1
2
3 1 For predicting 30-day mortality, the 30-day risk prediction model showed significantly better
4
5 2 predictive performance than both GRACE 1.0 and 2.0 scores (30-day risk model vs GRACE
6
7 3 1.0 score: C index, 0.855 [0.830-0.879] vs 0.771 [0.740-0.802]; NRI [95%CI], 0.412 [0.307-
8
9 4 0.485], $P < 0.0001$; IDI [95%CI], 0.048 [0.032-0.090], $P < 0.0001$; BIC, 3267.271 vs 3402.578;
10
11 5 30-day risk model vs GRACE 2.0 score: C index, 0.855 [0.830-0.879] vs 0.752 [0.720-0.784];
12
13 6 NRI [95%CI], 0.569 [0.500-0.624], $P < 0.0001$; IDI [95%CI], 0.061 [0.044-0.101], $P < 0.0001$;
14
15 7 BIC, 3247.357 vs 3492.004). Similarly, when predicting 2-year mortality, the 2-year risk
16
17 8 prediction model also performed better than the GRACE risk scores (2-year risk model vs
18
19 9 GRACE 1.0 score: C index, 0.825 [0.811-0.839] vs 0.798 [0.783-0.813]; NRI [95%CI], 0.191
20
21 10 [0.147-0.257], $P < 0.0001$; IDI [95%CI], 0.041 [0.031-0.057], $P < 0.0001$; BIC, 12540.559 vs
22
23 11 12697.527; 2-year risk model vs GRACE 2.0 score: C index, 0.825 [0.811-0.839] vs 0.769
24
25 12 [0.752-0.786]; NRI [95%CI], 0.486 [0.456-0.529], $P < 0.0001$; IDI [95%CI], 0.115 [0.098-
26
27 13 0.143], $P < 0.0001$; BIC, 12257.375 vs 12934.783). The decision curve analysis further
28
29 14 demonstrated better clinical utility of both 30-day and 2-year risk models than GRACE scores
30
31 15 (online supplemental figure 22 and 23).
32
33
34
35
36
37
38
39
40

41 ***Nomograms for dynamic risk prediction***

42
43
44 18 Two nomograms were created by assigning a weighted score based on regression coefficients
45
46 19 of each prognostic index for evaluating 30-day and 2-year mortality risk respectively. All
47
48 20 observed values of a prognostic index corresponded vertically to points on the top scale. The
49
50 21 sum of points for each index was plotted on the “Total points” scale, and corresponded to
51
52 22 mortality risk at the bottom (figure 1 and 2).
53
54
55

56 23 The 30-day prognostic nomogram achieved high discrimination in both derivation and
57
58 24 validation cohorts, with C indexes of 0.85 (95% CI: 0.83-0.88) and 0.79 (95% CI: 0.71-0.86)
59
60

1
2
3 1 respectively. The calibration curves presenting the concordance between observed and
4
5 2 predicted 30-day survival probability in two cohorts also showed satisfying calibration of the
6
7 3 model (online supplemental figure 24). In addition, the 30-day prognostic nomogram achieved
8
9 4 moderate to high discrimination (C indexes: 0.74 to 0.83) in subsets according to age, sex,
10
11 5 diabetes, AMI classification, PCI, and hospital level (online supplemental table 6).

12
13
14
15 6 The C indexes of 2-year prognostic nomogram were 0.83 (95% CI: 0.81-0.84) and 0.81
16
17 7 (95% CI: 0.79-0.84) in derivation and validation cohorts, respectively. The calibration curves
18
19 8 demonstrated excellent calibration of the nomogram in both derivation and validation cohorts
20
21 9 (online supplemental figure 25). In aforementioned subgroups of patients, the model
22
23 10 discrimination was acceptable (C index: 0.66 to 0.83, online supplemental table 7).
24
25
26
27
28
29
30
31

32 **Discussion**

33 13 Using data from a large, prospective, multicenter registry, we screened eleven predictors of 30-
34
35 14 day mortality, and fourteen variables, including heart failure worsening and medications within
36
37 15 30 days, associated with mortality between 30 days and 2 years in patients after AMI
38
39 16 hospitalization. These two sets of predictors were used to develop prognostic nomograms which
40
41 17 could predict post-discharge mortality for AMI patients in different time phases. The
42
43 18 nomograms showed satisfying discrimination and calibration in both derivation and validation
44
45 19 cohorts. This is a novel dynamic risk prediction tool which can serve for risk assessment and
46
47 20 guide long-term management of patients after AMI.
48
49
50
51

52 21 A series of risk models have been developed to predict mortality in patients with acute
53
54 22 coronary syndromes.^[6,7,17] These models mainly included prognostic factors obtained at
55
56 23 admission, and provided a fixed estimate of survival probability for a given patient. This
57
58 24 working mode of prognostic models was helpful for screening high-risk patients and
59
60

1
2
3 1 determining therapeutic strategies after admission. However, the incidence of adverse
4
5 2 cardiovascular events remained considerable after AMI hospitalization. Accumulating evidence
6
7
8 3 has implied that a larger proportion of adverse events occurred in the early phase after AMI
9
10 4 hospitalization,^[18] which reflected the changing risk following AMI and highlighted the
11
12 5 importance of risk reassessment during follow-up. Although some risk prediction models, such
13
14 6 as the GRACE risk score and dynamic Thrombolysis In Myocardial Infarction (TIMI) risk
15
16 7 score, could be used to assess mortality risk at discharge,^[6,9] none of them could improve
17
18 8 prognostic evaluation during follow-up. Considering the higher risk of adverse events in the
19
20 9 early period than that at the late stage after AMI hospitalization (online supplemental figure 6
21
22 10 and 7), we chose 30 days, which was also one of routine follow-up points after AMI
23
24 11 hospitalization in clinical practice, as the time point of risk reassessment to establish dynamic
25
26 12 risk prediction models.

27
28
29
30
31 13 The first model, which was developed to assess 30-day mortality risk at discharge in
32
33 14 patients after AMI, included variables related to patients' demographics, hemodynamics, left
34
35 15 ventricular systolic function, treatment, in-hospital adverse events, and medications at
36
37 16 discharge. Previous studies have established several risk prediction models, such as Platelet
38
39 17 glycoprotein IIb/IIIa in Unstable agina: Receptor Suppression Using Integrilin (eptifibatide)
40
41 18 Therapy (PURSUIT) and Zwolle risk scores,^[19,20] to predict 30-day mortality in patients with
42
43 19 acute coronary syndromes. However, these models mainly used patient characteristics, clinical
44
45 20 presentations at admission as well as angiographic features as prognostic indexes. The present
46
47 21 study showed that recurrent myocardial ischemia, recurrent myocardial infarction, heart failure
48
49 22 during AMI hospitalization, antiplatelet therapy, and statins use at discharge were
50
51 23 independently associated with short-term mortality after discharge, and provided significantly
52
53 24 incremental prognostic information over traditional predictive indexes. Therefore, these
54
55
56
57
58
59
60

1
2
3 1 adverse events and medications were included in the novel 30-day risk prediction model, which
4
5 2 might assist in decision-making of post-discharge management.
6
7

8 3 For the second model assessing 2-year mortality risk in 30-day survivors, we screened new
9
10 4 predictors including heart failure worsening within 30 days, antiplatelet therapy, β blocker, and
11
12 5 statins use within 30 days after discharge. A prior study showed that mortality rate of patients
13
14 6 with an early recurrent myocardial infarction (recurrent myocardial infarction within 90 days
15
16 7 of discharge) was nearly 50% within 5 years.^[21] In the present study, we observed that the
17
18 8 recurrent myocardial infarction and heart failure worsening within 30 days after discharge were
19
20 9 associated with >3-fold and >4.5-fold increase of 2-year mortality risk respectively in
21
22 10 univariable analysis, and heart failure worsening, which was included in 2-year prognostic
23
24 11 nomogram, was a statistically significant prognostic index in multivariable analysis. To our best
25
26 12 knowledge, this is the first prognostic instrument taking follow-up adverse event after AMI into
27
28 13 consideration. In addition, although some studies analyzed the prognostic impact of secondary
29
30 14 prevention implementation in patients after AMI,^[22,23] follow-up medications have not been
31
32 15 considered as predictive indexes in risk models for AMI so far. For some patients, not taking
33
34 16 optimal medical care within 30 days after discharge could be explained by poor medication
35
36 17 adherence after AMI, which was a problem for both developed and developing countries.^[23-25]
37
38 18 A study found that about 30% of patients with myocardial infarction who underwent PCI in the
39
40 19 United States reported suboptimal adherence to prescribed medications in six weeks after
41
42 20 hospitalization.^[25] Data from the China PEACE Prospective AMI study also showed that a
43
44 21 similar percentage of AMI patients did not take medications as prescribed in the first month
45
46 22 after discharge.^[23] Patients with early medication nonadherence not only suffered a higher risk
47
48 23 of early adverse events, but might not comply with long-term secondary prevention measures,
49
50 24 and therefore had poorer long-term prognosis. Another situation was that patients were not
51
52 25 prescribed with some medications by physicians, due to contraindications or high risk of side
53
54
55
56
57
58
59
60

1
2
3 1 effects. However, lack of secondary prevention medications after AMI still meant a higher risk
4
5 2 of cardiovascular adverse events in these patients. Indeed, our analysis showed that insufficient
6
7
8 3 use of antiplatelet therapy, β blocker, and statins within 30 days after AMI hospitalization had
9
10 4 significant negative impact on 2-year survival. The inclusion of follow-up medications and
11
12 5 adverse events improved risk prediction of 2-year risk prediction model.
13
14

15 6 Although a previous study from CAMI registry showed that there were significant
16
17 7 variations in in-hospital mortality among three levels of hospitals in China,^[14] hospital level
18
19
20 8 was not used as a predictive index in the present risk prediction models, for the improvement
21
22 9 of care quality in relatively low-level hospitals was likely to weaken its prognostic value.
23
24 10 Besides, the hospital level was showed to provide no additional prognostic information beyond
25
26
27 11 current predictors in the risk prediction models. Socioeconomic factors, which were known as
28
29 12 risk factors for survival following myocardial infarction,^[26-29] were not included in the present
30
31 13 models because we sought to develop models based on predictors directly reflecting patients'
32
33
34 14 clinical conditions. Notably, these factors were also not included in existing risk prediction
35
36 15 tools.^[6,7,9,16] The rates of COPD and prior heart failure in our cohort were lower than the United
37
38 16 Kingdom population of AMI.^[30] However, the rates in the present study were similar with data
39
40
41 17 from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome
42
43 18 project, which was also a nationwide registry in China.^[31,32] The distinct prevalence of
44
45 19 comorbidity in patients with myocardial infarction between countries highlighted the
46
47 20 importance of developing risk prediction model for specific population.
48
49

50 21 The present study showed that the dynamic prognostic nomograms achieved satisfying
51
52 22 discrimination and calibration, and performed well in subgroups of patients according to age,
53
54 23 sex, diabetes, AMI classification, PCI, and hospital level. The clinical utility of nomograms
55
56
57 24 was further confirmed by decision curve analysis. Prognostic nomogram is a graphical
58
59 25 presentation format for complex predictive regression model.^[33] A series of prognostic

1
2
3 1 nomograms have been established for risk prediction in patients with cancer or cardiovascular
4
5 2 diseases.^[34-39] For patients with myocardial infarction, previous prognostic nomograms mainly
6
7
8 3 focused on evaluating short-term risk of mortality or other adverse events.^[37,38] There also
9
10 4 existed nomogram developed to predict risk of adverse events beyond 1 year.^[36] However,
11
12 5 without consideration of changing nature of event risk or medications, the nomogram might not
13
14 6 play roles in post-discharge management of patients. Our prognostic nomograms, which took
15
16
17 7 into account follow-up adverse event as well as medications, could assist in risk reassessment
18
19 8 at 30 days after discharge. In detail, using the nomogram for prediction of 30-day mortality,
20
21 9 physicians can identify high-risk patients at discharge. At 30-day follow up, the second
22
23
24 10 nomogram can be used to reassess mortality risk of 30-day survivors, and may guide decision-
25
26 11 making of long-term follow-up intensity and strategies of medical care.

32 13 **Limitations**

33
34
35 14 Several important limitations in this study should be mentioned. First, as a retrospective
36
37 15 analysis of a prospective cohort, this study only used data which had been collected in the
38
39 16 CAMI registry. Although the present risk prediction tool has achieved satisfying discrimination
40
41
42 17 and calibration, it may be further improved by including other prognostic factors of AMI, such
43
44 18 as details of angiographic characteristics, which were not available in a large proportion of the
45
46 19 cohort. Heart failure worsening and medications within 30 days after discharge were included
47
48 20 in the 2-year risk prediction model. However, lifestyle interventions and cardiac rehabilitation
49
50 21 programmes, which were associated with lower risk of adverse events in patients with coronary
51
52 22 artery disease,^[40,41] as well as laboratory and echocardiographic indexes were not collected
53
54
55 23 during follow up. These variables may also improve the predictive performance of the models.
56
57 24
58 24 Second, although the present study showed the feasibility of assessing 2-year prognosis at 30
59
60 25 days after discharge, risk reassessment is a serial process and ideally performed at more time

1
2
3 1 points beyond the early phase after discharge. Models which can ensure more dynamic and
4
5 2 accurate risk prediction are still needed. Third, the distribution of AMI types (types 1, 2, 3, 4b,
6
7 and 4c) was not collected in the CAMI registry. Results of the present study could have biased
8
9 if a certain type was more represented than another. However, the CAMI registry enrolled
10
11 4 patients consecutively from 108 hospitals, which meant that it was representative of AMI
12
13 5 population in routine clinical practice. It is plausible that the impact of distribution of AMI
14
15 6 types is relatively limited. Fourth, there existed some missing values which needed to be
16
17 7 imputed before regression analysis. However, almost all predictors had missing values of <6%.
18
19 8 Finally, our dynamic models were only internally validated in Chinese patients. Further
20
21 9 validations in external cohorts including patients of other races are needed.
22
23
24 10
25
26
27 11
28

29 12 **Conclusions**

30
31
32 13 The dynamic risk prediction tool consisted of a short-term prognostic model and a long-term
33
34 14 prognostic model for patients after AMI hospitalization. Taking the changing nature of adverse
35
36 15 events and medications into consideration, the models can serve prospective risk stratification
37
38 16 and guide post-discharge management of AMI. Dynamic risk prediction may play an important
39
40 17 role in therapeutic decision-making and quality improvement of secondary prevention after
41
42 18 AMI hospitalization.
43
44
45
46
47 19
48
49

50 20 **Acknowledgments**

51
52 21 We appreciate all staff and investigators for their contributions to the CAMI registry.
53
54
55 22
56
57

58 23 **Contributors**

1
2
3 1 HX and YYang contributed significantly to the conception, design, and conduction of this study.
4
5 2 JL and CW wrote the initial manuscript. CW, YZ, and YW provided strong support in statistical
6
7 3 analysis. JL, CW, XG, JY, XZ, YYe, QD, RF, HS, XY, YZ, YW, HX, and YYang contributed
8
9 4 significantly to revisions of manuscript, analysis, and interpretation of data. All authors
10
11 5 contributed substantially to this study and approved its submission.
12
13
14
15
16
17

18 7 **Funding**

19
20
21 8 This work was supported by the Twelfth Five-Year Planning Project of the Scientific and
22
23 9 Technological Department of China [grant number 2011BAI11B02] and Beijing Nova Program
24
25 [grant number Z211100002121063].
26
27
28
29
30
31

32 12 **Competing Interests**

33
34
35 13 None declared.
36
37
38
39
40
41

42 15 **Patient consent for publication**

43
44 16 Not required.
45
46
47
48
49
50

51 18 **Ethics approval**

52
53 19 The CAMI registry conformed to the ethical guidelines of the Declaration of Helsinki, and was
54
55 20 approved by the institutional review board central committee at Fuwai Hospital, National
56
57 21 Center for Cardiovascular Diseases of China (Approval No. 2012-431). Written informed
58
59 22 consent was given by eligible patients before registration.
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9

Data Availability Statement

Data are available on reasonable request from the corresponding authors.

References

1. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J* 2008;156:1045-55.
2. Yamamoto T, Yoshida N, Takayama M; Tokyo CCU Network. Temporal trends in acute myocardial infarction incidence and mortality between 2006 and 2016 in Tokyo - Report from the Tokyo CCU Network. *Circ J* 2019;83:1405-9.
3. Chaudhry SI, Khan RF, Chen J, et al. National trends in recurrent AMI hospitalizations 1 year after acute myocardial infarction in Medicare beneficiaries: 1999-2010. *J Am Heart Assoc* 2014;3:e001197.
4. Ergatoudes C, Thunström E, Rosengren A, et al. Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome. *BMC Cardiovasc Disord* 2016;16:226.
5. Zhao Q, Xu H, Zhang X, et al. Current status and hospital-level differences in care and outcomes of patients with acute non-ST-segment elevation myocardial infarction in China: insights from China Acute Myocardial Infarction Registry. *Front Cardiovasc Med* 2022;8:800222.
6. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. *JAMA* 2004;291:2727-33.
7. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. *JAMA* 2000;284:835-42.

- 1
2
3 1 8. Chang WC, Boersma E, Granger CB, et al. Dynamic prognostication in non-ST-elevation
4
5 2 acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. *Am Heart J*
6
7 3 2004;148:62-71.
- 8
9
10 4 9. Amin ST, Morrow DA, Braunwald E, et al. Dynamic TIMI risk score for STEMI. *J Am*
11
12 5 *Heart Assoc* 2013;2:e003269.
- 13
14
15 6 10. Chang WC, Kaul P, Fu Y, et al. Forecasting mortality: dynamic assessment of risk in ST-
16
17 7 segment elevation acute myocardial infarction. *Eur Heart J* 2006;27:419-26.
- 18
19
20 8 11. Westerhout CM, Pieper KS, James SK, et al. Dynamic modeling of 90-day mortality in
21
22 9 ST-elevation myocardial infarction patients undergoing primary percutaneous coronary
23
24 10 intervention. *Am Heart J* 2013;165:354-62.e2.
- 25
26
27 11 12. Xu H, Li W, Yang J, et al. Tal Infarction (CAMI) Registry: a national long-term registry-
28
29 12 research-education integrated platform for exploring acute myocardial infarction in China.
30
31 13 *Am Heart J* 2016;175:193-201.e3.
- 32
33
34 14 13. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction.
35
36 15 *Circulation* 2012;126:2020-35.
- 37
38
39 16 14. Xu H, Yang Y, Wang C, et al. Association of hospital-level differences in care with
40
41 17 outcomes among patients with acute ST-segment elevation myocardial infarction in China.
42
43 18 *JAMA Netw Open* 2020;3:e2021677.
- 44
45
46 19 15. Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a
47
48 20 clinical prediction model. *BMJ* 2020;368:m441.
- 49
50
51 21 16. Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be
52
53 22 stratified for management according to their risk? Derivation, external validation and
54
55 23 outcomes using the updated GRACE risk score. *BMJ Open* 2014;4:e004425.
- 56
57
58
59
60

- 1
2
3 1 17. McNamara RL, Kennedy KF, Cohen DJ, et al. Predicting in-hospital mortality in
4
5 2 patients with acute myocardial infarction. *J Am Coll Cardiol* 2016;68:626-35.
6
7
8 3 18. Song J, Murugiah K, Hu S, et al. Incidence, predictors, and prognostic impact of recurrent
9
10 4 acute myocardial infarction in China. *Heart* 2020;107:313-8.
11
12
13 5 19. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute
14
15 6 coronary syndromes without persistent ST-segment elevation. Results from an
16
17 7 international trial of 9461 patients. The PURSUIT Investigators. *Circulation*
18
19 8 2020;101:2557-67.
20
21
22
23 9 20. De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of patients with
24
25 10 acute myocardial infarction treated with primary angioplasty: implications for early
26
27 11 discharge. *Circulation* 2004;109:2737-43.
28
29
30
31 12 21. Nair R, Johnson M, Kravitz K, et al. Characteristics and outcomes of early recurrent
32
33 13 myocardial infarction after acute myocardial infarction. *J Am Heart Assoc*
34
35 14 2021;10:e019270.
36
37
38
39 15 22. Chow CK, Brieger D, Ryan M, et al. Secondary prevention therapies in acute coronary
40
41 16 syndrome and relation to outcomes: observational study. *Heart Asia* 2019;11:e011122.
42
43
44 17 23. Shang P, Liu GG, Zheng X, et al. Association between medication adherence and 1-year
45
46 18 major cardiovascular adverse events after acute myocardial infarction in China. *J Am Heart*
47
48 19 *Assoc* 2019;8:e011793.
49
50
51 20 24. Rymer J, McCoy LA, Thomas L, et al. Persistence of evidence-based medication use after
52
53 21 discharge from academic versus nonacademic hospitals among patients with non-ST-
54
55 22 segment elevation myocardial infarction. *Am J Cardiol* 2014;114:1479-84.
56
57
58
59
60

- 1
2
3 1 25. Mathews R, Peterson ED, Honeycutt E, et al. Early medication nonadherence after acute
4
5 2 myocardial infarction: insights into actionable opportunities from the Treatment with ADP
6
7 3 receptor inhibitorS: Longitudinal Assessment of Treatment Patterns and Events after
8
9 4 Acute Coronary Syndrome (TRANSLATE-ACS) Study. *Circ Cardiovasc Qual Outcomes*
10
11 2015;8:347-56.
12
13
14
15 6 26. Machón M, Aldasoro E, Martínez-Cambor P, et al. Socioeconomic differences in
16
17 7 incidence and relative survival after a first acute myocardial infarction in the Basque
18
19 8 Country, Spain. *Gac Sanit* 2012;26:16-23.
20
21
22
23 9 27. Alter DA, Franklin B, Ko DT, et al. Socioeconomic status, functional recovery, and long-
24
25 10 term mortality among patients surviving acute myocardial infarction. *PLoS One*
26
27 11 2013;8:e65130.
28
29
30 12 28. Bucholz EM, Ma S, Normand SL, et al. Race, socioeconomic status, and life expectancy
31
32 13 after acute myocardial infarction. *Circulation* 2015;132:1338-46.
33
34
35
36 14 29. Tetzlaff J, Tetzlaff F, Geyer S, et al. Widening or narrowing income inequalities in
37
38 15 myocardial infarction? Time trends in life years free of myocardial infarction and after
39
40 16 incidence. *Popul Health Metr* 2021;19:47.
41
42
43
44 17 30. Rothnie KJ, Smeeth L, Pearce N, et al. Predicting mortality after acute coronary syndromes
45
46 18 in people with chronic obstructive pulmonary disease. *Heart* 2016;102:1442-8.
47
48
49 19 31. Cai X, Zhou J, Li W, et al. Potential influential factors of in-hospital myocardial
50
51 20 reinfarction in ST-segment elevation myocardial infarction (STEMI) patients: finding from
52
53 21 the Improving Care for Cardiovascular Disease in China- (CCC-) Acute Coronary
54
55 22 Syndrome (ACS) project. *Oxid Med Cell Longev* 2021;2021:9977312.
56
57
58
59
60

- 1
2
3 1 32. Sun H, Li Z, Song X, et al. Revisiting the lipid paradox in ST-elevation myocardial
4
5 2 infarction in the Chinese population: findings from the CCC-ACS project. *Eur Heart J*
6
7 3 *Acute Cardiovasc Care* 2021;10:978-987.
8
9
10 4 33. Bonnett LJ, Snell KIE, Collins GS, et al. Guide to presenting clinical prediction models for
11
12 5 use in clinical settings. *BMJ* 2019;365:1737.
13
14
15 6 34. Yan B, Su BB, Bai DS, et al. A practical nomogram and risk stratification system predicting
16
17 7 the cancer-specific survival for patients with early hepatocellular carcinoma. *Cancer Med*
18
19 8 2021;10:496-506.
20
21
22 9 35. Ó Hartaigh B, Gransar H, Callister T, et al. Development and validation of a simple-to-use
23
24 10 nomogram for predicting 5-, 10-, and 15-year survival in asymptomatic adults undergoing
25
26 11 coronary artery calcium scoring. *JACC Cardiovasc Imaging* 2018;11:450-8.
27
28
29 12 36. Zhao X, Liu C, Zhou P, et al. Estimation of major adverse cardiovascular events in patients
30
31 13 with myocardial infarction undergoing primary percutaneous coronary intervention: A risk
32
33 14 prediction score model from a derivation and validation study. *Front Cardiovasc Med*
34
35 15 2020;7:603621.
36
37
38 16 37. Guo Q, Wu M, Li H, et al. Development and validation of a prognostic nomogram for
39
40 17 myocardial infarction patients in intensive care units: a retrospective cohort study. *BMJ*
41
42 18 *Open* 2020;10:e040291.
43
44
45 19 38. Zheng X, Huang R, Liu G, et al. Development and verification of a predictive nomogram
46
47 20 to evaluate the risk of complicating ventricular tachyarrhythmia after acute myocardial
48
49 21 infarction during hospitalization: A retrospective analysis. *Am J Emerg Med* 2021;46:462-
50
51 22 8.
52
53
54
55
56
57
58
59
60

- 1
2
3 1 39. Wang H, Liu D, Liang H, et al. A nomogram for predicting survival in patients with
4
5 2 colorectal cancer incorporating cardiovascular comorbidities. *Front Cardiovasc Med*
6
7 3 2022;9:875560.
8
9
10 4 40. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking
11
12 5 modification with risk of early cardiovascular events after acute coronary syndromes.
13
14 6 *Circulation* 2010;121:750-8.
15
16
17 7 41. Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for
18
19 8 coronary heart disease: cochrane systematic review and meta-analysis. *J Am Coll Cardiol*
20
21 9 2016;67:1-12.
22
23
24
25
26 10
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Table 1. Baseline characteristics of cohorts for developing and validating 30-day**
4
5 **prognostic model**
6
7

Variables	Derivation cohort (n=15925)	Validation cohort (n=7962)
Demographics		
Age, yrs	62.27±12.36	62.54±12.29
Female	3878 (24.4)	1940 (24.4)
BMI, kg/m ²	24.13±3.05	24.08±3.04
Medical history		
Diabetes	2943 (19.6)	1505 (20.0)
Hypertension	7873 (51.2)	3897 (50.8)
Hyperlipidemia	1154 (8.5)	569 (8.3)
Current smoker	7083 (45.7)	3483 (44.8)
Prior angina pectoris	4044 (27.8)	1994 (27.4)
Prior myocardial infarction	1083 (7.4)	553 (7.5)
Prior heart failure	329 (2.2)	169 (2.3)
Prior PCI	753 (5.0)	381 (5.1)
Prior CABG	56 (0.4)	36 (0.5)
Prior renal dysfunction	197 (1.3)	94 (1.3)
COPD	279 (1.9)	142 (1.9)

Presenting characteristics

Symptom onset to admission time

0-6h	7398 (47.0)	3625 (46.0)
>6h	8330 (53.0)	4247 (54.0)

Heart rate, beats/min

77±18	78±18
-------	-------

Systolic blood pressure

129.48±25.01	129.94±25.26
--------------	--------------

Killip class

I	11836 (76.2)	5903 (75.8)
II-IV	3694 (23.8)	1883 (24.2)

Cardiac arrest at admission

128 (0.8)	77 (1.0)
-----------	----------

AMI classification

STEMI	12051 (75.7)	5991 (75.2)
NSTEMI	3874 (24.3)	1971 (24.8)

Anterior wall involvement

7406 (47.7)	3696 (47.5)
-------------	-------------

Values are shown as mean ± standard deviation, median (interquartile range), or number (%) without imputation of missing data. BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction.

1 **Table 2. Multivariable analysis of 30-day mortality in the derivation cohort**

	All-cause death	
	Adjusted HR (95% CI)	P value
Age (per 1 year increase)	1.035 (1.021, 1.049)	<0.0001
Prior stroke (vs no)	1.560 (1.091-2.231)	0.0148
Heart rate (per 1beat/min increase)	1.006 (1.000-1.012)	0.0497
Killip class II -IV(vs I)	1.528 (1.115-2.094)	0.0083
LVEF (per 1% increase)	0.969 (0.955, 0.982)	<0.0001
In-hospital PCI (vs no)	0.441 (0.307, 0.634)	<0.0001
In-hospital recurrent myocardial ischemia (vs no)	1.711 (1.019-2.871)	0.0421
In-hospital recurrent myocardial infarction (vs no)	4.572 (2.121-9.859)	0.0001
In-hospital heart failure (vs no)	2.869 (2.065-3.986)	<0.0001
Antiplatelet therapy at discharge (vs dual antiplatelet therapy)		
Single antiplatelet therapy	0.791 (0.491-1.275)	0.3358
None	2.363 (1.395-4.003)	0.0014
Statins at discharge (vs no)	2.009 (1.258-3.208)	0.0035

2 LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; HR, hazard
3 ratio; CI, confidence interval.

4

1
2
3 **1 Table 3. Multivariable analysis of mortality after 30 days in the derivation cohort**
4
5

	All-cause death	
	Adjusted HR (95% CI)	P value
Age (per 1 year increase)	1.052 (1.045-1.060)	<0.0001
Prior renal dysfunction (vs no)	1.539 (1.076-2.201)	0.0181
History of heart failure (vs no)	1.501 (1.160-1.943)	0.0020
STEMI (vs NSTEMI)	0.747 (0.639-0.873)	0.0002
Heart rate (per 1 beat/min increase)	1.008 (1.005-1.011)	<0.0001
Killip class II -IV(vs I)	1.330 (1.129-1.566)	0.0006
Hemoglobin (per 1g/L increase)	0.993 (0.990-0.996)	<0.0001
LVEF (per 1% increase)	0.971 (0.964-0.978)	<0.0001
In-hospital PCI (vs no)	0.423 (0.351-0.510)	<0.0001
In-hospital heart failure(vs no)	1.287 (1.085-1.525)	0.0037
Heart failure worsening within 30 days (vs no)	1.675 (1.258-2.229)	0.0004
Antiplatelet therapy within 30 days (vs dual antiplatelet therapy)		
Single antiplatelet therapy	1.107 (0.911-1.345)	0.3084
None	1.430 (1.055-1.937)	0.0211
β blocker within 30 days (vs yes)	1.271 (1.085-1.491)	0.0031
Statins within 30 days (vs yes)	1.191 (0.908-1.561)	0.2075

1
2
3 1 STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation
4
5 2 myocardial infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
6
7 3 intervention; HR, hazard ratio; CI, confidence interval.
8
9
10
11 4
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4. Comparison of 30-day prognostic models with or without adverse events and medications

	30-day model 0	30-day model 1
C index	0.822 (0.796-0.848)	0.855 (0.830-0.879)
NRI (95%CI)		0.445 (0.339-0.523)
P value		<0.0001
IDI (95%CI)		0.040 (0.025-0.074)
P value		<0.0001
Likelihood ratio test (P value)		<0.0001
BIC	3434.091	3350.882

30-days Model 0: age, prior stroke, heart rate, Killip class, LVEF, and in-hospital PCI. 30-day Model 1: age, prior stroke, heart rate, Killip class, LVEF, in-hospital PCI, in-hospital recurrent myocardial ischemia, in-hospital recurrent myocardial infarction, in-hospital heart failure, antiplatelet therapy, and statins at discharge. LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; NRI, net reclassification index; CI, confidence interval; IDI, integrated discrimination improvement index; BIC, Bayesian information criteria.

Table 5. Comparison of 2-year prognostic models with or without adverse events and medications


	2-year model 0	2-year model 1
C index	0.822 (0.807-0.836)	0.825 (0.811-0.839)
NRI (95%CI)		0.119 (-0.045-0.176)
P value		0.126
IDI (95%CI)		0.008 (0.004-0.017)
P value		0.007
Likelihood ratio test (P value)		<0.0001
BIC	12792.602	12785.706

2-year Model 0: age, prior renal dysfunction, prior heart failure, AMI classification, heart rate, Killip class, hemoglobin, LVEF, in-hospital PCI, and in-hospital heart failure. 2-year Model 1: age, prior renal dysfunction, prior heart failure, AMI classification, heart rate, Killip class, hemoglobin, LVEF, in-hospital PCI, in-hospital heart failure, heart failure worsening within 30 days, antiplatelet therapy, β blockers, and statins within 30 days. AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; NRI, net reclassification index; CI, confidence interval; IDI, integrated discrimination improvement index; BIC, Bayesian information criteria.


1
2
3 **1 FIGURE LEGENDS**
4
5

6 **2 Figure 1. Nomogram for predicting 30-day mortality risk.** The observed value of a
7
8 **3** prognostic index was assigned a point by drawing a perpendicular line towards the top scale.
9
10 **4** The sum of points for each index was plotted on the “Total points” scale, and corresponded to
11
12 **5** the risk of 30-day mortality at the bottom with a vertical line. LVEF, left ventricular ejection
13
14 **6** fraction; PCI, percutaneous coronary intervention.
15
16
17

18 **7**
19
20
21 **8 Figure 2. Nomogram for predicting 2-year mortality risk.** The observed value of a
22
23 **9** prognostic index was assigned a point by drawing a perpendicular line towards the top scale.
24
25 **10** The sum of points for each index was plotted on the “Total points” scale, and corresponded to
26
27 **11** the risk of 2-year mortality at the bottom with a vertical line. AMI, acute myocardial infarction;
28
29 **12** LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.
30
31
32
33
34 **13**
35
36 **14**
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Supplemental Materials

Junxing Lv et al. Development and validation of dynamic models to predict post-discharge mortality risk in patients with acute myocardial infarction: results from China Acute Myocardial Infarction registry.

I. Supplemental Tables.

Supplemental Table 1. Number of missing values for selected predictors in derivation and validation cohorts.

Supplemental Table 2. Baseline characteristics, medications, and outcomes of cohorts for developing and validating 30-day prognostic model.

Supplemental Table 3. Baseline characteristics, medications, and outcomes of cohorts for developing and validating 2-year prognostic model.

Supplemental Table 4. Univariable analysis of 30-day mortality.

Supplemental Table 5. Univariable analysis of mortality after 30 days.

Supplemental Table 6. Discrimination of 30-day prognostic nomogram in subgroups of patients.

Supplemental Table 7. Discrimination of 2-year prognostic nomogram in subgroups of patients.

II. Supplemental Figures.

Supplemental Figure 1. Flowchart of this study. AMI, acute myocardial infarction.

Supplemental Figure 2. Martingale residual plots for testing the linearity assumption before developing the 30-day model. LVEF, left ventricular ejection fraction.

1
2
3 **Supplemental Figure 3. Martingale residual plots for testing the linearity assumption**
4 **before developing the 2-year model.** LVEF, left ventricular ejection fraction.
5
6
7

8 **Supplemental Figure 4. Schoenfeld residual plots for testing the proportional hazards**
9 **assumption before developing the 30-day model.** LVEF, left ventricular ejection fraction;
10 PCI, percutaneous coronary intervention; HF, heart failure; reMI, recurrent myocardial
11 infarction.
12
13
14

15
16 **Supplemental Figure 5. Schoenfeld residual plots for testing the proportional hazards**
17 **assumption before developing the 2-year model.** LVEF, left ventricular ejection fraction;
18 HF, heart failure; AMI, acute myocardial infarction; PCI, percutaneous coronary intervention.
19
20
21

22
23 **Supplemental Figure 6. Kaplan-Meier curve for patients after AMI hospitalization.** AMI,
24 acute myocardial infarction.
25
26
27

28
29 **Supplemental Figure 7. Density plots for all-cause death and recurrent myocardial**
30 **infarction during follow-up.** (A) Density plot for all-cause death. (B) Density plot for
31 recurrent myocardial infarction.
32
33

34
35 **Supplemental Figure 8. Variable selection by LASSO method for 30-day prognostic**
36 **model in imputation dataset 1.** (A) The plot showing partial likelihood deviance values
37 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
38 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
39 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
40 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
41 shrinkage and selection operator; SE, standard error.
42
43
44

45
46 **Supplemental Figure 9. Variable selection by LASSO method for 30-day prognostic**
47 **model in imputation dataset 2.** (A) The plot showing partial likelihood deviance values
48 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
49 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
50 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
51 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
52 shrinkage and selection operator; SE, standard error.
53
54
55

56
57 **Supplemental Figure 10. Variable selection by LASSO method for 30-day prognostic**
58 **model in imputation dataset 3.** (A) The plot showing partial likelihood deviance values
59 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
60 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The

1
2
3 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
4 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
5 shrinkage and selection operator; SE, standard error.
6
7
8

9
10 **Supplemental Figure 11. Variable selection by LASSO method for 30-day prognostic**
11 **model in imputation dataset 4.** (A) The plot showing partial likelihood deviance values
12 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
13 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
14 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
15 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
16 shrinkage and selection operator; SE, standard error.
17
18
19

20
21 **Supplemental Figure 12. Variable selection by LASSO method for 30-day prognostic**
22 **model in imputation dataset 5.** (A) The plot showing partial likelihood deviance values
23 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
24 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
25 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
26 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
27 shrinkage and selection operator; SE, standard error.
28
29
30

31 **Supplemental Figure 13. Relative importance of selected predictors for 30-day mortality.**
32 Relative importance of variables selected by LASSO method was ranked according to the
33 proportion of explainable log-likelihood ratio χ^2 statistics. LASSO, least absolute shrinkage
34 and selection operator; Mi, myocardial ischemia; MI, myocardial infarction; PCI,
35 percutaneous coronary intervention; LVEF, left ventricular ejection fraction; HF, heart failure.
36
37
38
39

40
41 **Supplemental Figure 14. Variable selection by LASSO method for 2-year prognostic**
42 **model in imputation dataset 1.** (A) The plot showing partial likelihood deviance values
43 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
44 were drawn at values by the minimum criteria and the 1 SE of minimum criteria. The lambda
45 with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile
46 plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute shrinkage and
47 selection operator; SE, standard error.
48
49
50

51
52 **Supplemental Figure 15. Variable selection by LASSO method for 2-year prognostic**
53 **model in imputation dataset 2.** (A) The plot showing partial likelihood deviance values
54 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
55 were drawn at values by the minimum criteria and the 1 SE of minimum criteria. The lambda
56 with 1 SE of minimum deviance was used for variable selection. (B) The coefficient profile
57 plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute shrinkage and
58 selection operator; SE, standard error.
59
60

1
2
3 **Supplemental Figure 16. Variable selection by LASSO method for 2-year prognostic**
4 **model in imputation dataset 3.** (A) The plot showing partial likelihood deviance values
5 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
6 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
7 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
8 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
9 shrinkage and selection operator; SE, standard error.
10
11
12
13

14 **Supplemental Figure 17. Variable selection by LASSO method for 2-year prognostic**
15 **model in imputation dataset 4.** (A) The plot showing partial likelihood deviance values
16 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
17 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
18 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
19 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
20 shrinkage and selection operator; SE, standard error.
21
22
23
24

25 **Supplemental Figure 18. Variable selection by LASSO method for 2-year prognostic**
26 **model in imputation dataset 5.** (A) The plot showing partial likelihood deviance values
27 versus $\log(\lambda)$. Tuning parameter λ selection used 10-fold cross-validation. The vertical lines
28 were drawn at optimal values by the minimum criteria and the 1 SE of minimum criteria. The
29 lambda with 1 SE of minimum deviance was used for variable selection. (B) The coefficient
30 profile plot. The plot was produced against the $\log(\lambda)$ sequence. LASSO, least absolute
31 shrinkage and selection operator; SE, standard error.
32
33
34
35

36 **Supplemental Figure 19. Relative importance of selected predictors for 2-year mortality.**
37 Relative importance of variables selected by LASSO method was ranked according to the
38 proportion of explainable log-likelihood ratio χ^2 statistics. LASSO, least absolute shrinkage
39 and selection operator; HF, heart failure; AMI, acute myocardial infarction; LVEF, left
40 ventricular ejection fraction; PCI, percutaneous coronary intervention.
41
42
43
44

45 **Supplemental Figure 20. Comparisons of clinical utility between models with or without**
46 **adverse events and medications.** The red and green lines represent the assumption that all or
47 none patients at high risk with different thresholds. The lines in the upper right represent the
48 risk prediction models. (A) Comparison of clinical utility between 30-day model with or
49 without adverse events and medications. (B) Comparison of clinical utility between 2-year
50 model with or without adverse events and medications.
51
52
53
54

55 **Supplemental Figure 21. Comparisons of clinical utility between models with or without**
56 **hospital level.** The red and green lines represent the assumption that all or none patients at
57 high risk with different thresholds. The lines in the upper right represent the risk prediction
58 models. (A) Comparison of clinical utility between 30-day model with or without hospital
59
60

1
2
3 level. (B) Comparison of clinical utility between 2-year model with or without hospital level.
4
5
6

7 **Supplemental Figure 22. Comparisons of clinical utility between models and GRACE 1.0**
8 **score.** The red and green lines represent the assumption that all or none patients at high risk
9 with different thresholds. The lines in the upper right represent the risk prediction models. (A)
10 Comparison of clinical utility between 30-day model and GRACE 1.0 score. (B) Comparison
11 of clinical utility between 2-year model and GRACE 1.0 score. GRACE, Global Registry of
12 Acute Coronary Events.
13
14
15
16
17

18 **Supplemental Figure 23. Comparisons of clinical utility between models and GRACE 2.0**
19 **score.** The red and green lines represent the assumption that all or none patients at high risk
20 with different thresholds. The lines in the upper right represent the risk prediction models. (A)
21 Comparison of clinical utility between 30-day model and GRACE 2.0 score. (B) Comparison
22 of clinical utility between 2-year model and GRACE 2.0 score. GRACE, Global Registry of
23 Acute Coronary Events.
24
25
26
27
28

29 **Supplemental Figure 24. Calibration curves of 30-day prognostic nomogram.** Calibration
30 curves present the relationship between observed and predicted survival probabilities by 30-
31 day prognostic nomogram in both derivation and validation cohorts. (A) Calibration curve of
32 30-day prognostic nomogram in derivation cohort. (B) Calibration curve of 30-day prognostic
33 nomogram in validation cohort.
34
35
36
37
38

39 **Supplemental Figure 25. Calibration curves of 2-year prognostic nomogram.** Calibration
40 curves present the relationship between observed and predicted survival probabilities by 2-
41 year prognostic nomogram in both derivation and validation cohorts. (A) Calibration curve of
42 2-year prognostic nomogram in derivation cohort. (B) Calibration curve of 2-year prognostic
43 nomogram in validation cohort.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **I. Supplemental Tables.**
4

5 **Supplemental Table 1. Number of missing values for selected predictors in derivation**
6 **and validation cohorts**
7

	Number of missing values (%)
Derivation cohort	
30-day prognostic model	
Age	336 (2.1)
Prior stroke	820 (5.1)
Heart rate	391 (2.5)
Killip class	395 (2.5)
LVEF	3370 (21.2)
In-hospital PCI	435 (2.7)
In-hospital recurrent myocardial ischemia	518 (3.3)
In-hospital recurrent myocardial infarction	518 (3.3)
In-hospital heart failure	502 (3.2)
Antiplatelet therapy at discharge	849 (5.3)
Statins at discharge	849 (5.3)
2-year prognostic model	
Age	242 (2.0)
Prior renal dysfunction	510 (4.2)
History of heart failure	490 (4.0)
AMI classification	0 (0.0)
Heart rate	107 (0.9)
Killip class	114 (0.9)
Hemoglobin	327 (2.7)
LVEF	2307 (19.0)
In-hospital PCI	130 (1.1)
In-hospital heart failure	155 (1.3)
Heart failure worsening within 30 days	8 (0.1)
Antiplatelet therapy within 30 days	0 (0.0)
β blockers within 30 days	0 (0.0)
Statins within 30 days	0 (0.0)

Validation cohort

30-day prognostic model

Age	144 (1.8)
Prior stroke	404 (5.1)
Heart rate	197 (2.5)
Killip class	176 (2.2)
LVEF	1678 (21.1)
In-hospital PCI	216 (2.7)
In-hospital recurrent myocardial ischemia	267 (3.4)
In-hospital recurrent myocardial infarction	261 (3.3)
In-hospital heart failure	254 (3.2)
Antiplatelet therapy at discharge	416 (5.2)
Statins at discharge	416 (5.2)

2-year prognostic model

Age	106 (1.7)
Prior renal dysfunction	260 (4.3)
History of heart failure	254 (4.2)
AMI classification	0 (0.0)
Heart rate	75 (1.2)
Killip class	54 (0.9)
Hemoglobin	135 (2.2)
LVEF	1161 (19.1)
In-hospital PCI	60 (1.0)
In-hospital heart failure	83 (1.4)
Heart failure worsening within 30 days	9 (0.1)
Antiplatelet therapy within 30 days	0 (0.0)
β blockers within 30 days	0 (0.0)
Statins within 30 days	0 (0.0)

LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; AMI, acute myocardial infarction.

Supplemental Table 2. Baseline characteristics, medications, and outcomes of cohorts for developing and validating 30-day prognostic model

Variables	Derivation cohort (n=15925)	Validation cohort (n=7962)
Demographics		
Age, yrs	62.27±12.36	62.54±12.29
Female	3878 (24.4)	1940 (24.4)
BMI, kg/m ²	24.13±3.05	24.08±3.04
Medical history		
Diabetes	2943 (19.6)	1505 (20.0)
Hypertension	7873 (51.2)	3897 (50.8)
Hyperlipidemia	1154 (8.5)	569 (8.3)
Current smoker	7083 (45.7)	3483 (44.8)
Prior angina pectoris	4044 (27.8)	1994 (27.4)
Prior myocardial infarction	1083 (7.4)	553 (7.5)
Prior heart failure	329 (2.2)	169 (2.3)
Prior stroke	1330 (8.8)	711 (9.4)
Prior peripheral artery disease	96 (0.6)	46 (0.6)
Prior PCI	753 (5.0)	381 (5.1)
Prior CABG	56 (0.4)	36 (0.5)
Prior renal dysfunction	197 (1.3)	94 (1.3)
COPD	279 (1.9)	142 (1.9)
Presenting characteristics		
Symptom onset to admission time		
0-6h	7398 (47.0)	3625 (46.0)
>6h	8330 (53.0)	4247 (54.0)
Heart rate, beats/min	77±18	78±18
Systolic blood pressure	129.48±25.01	129.94±25.26
Killip class		
I	11836 (76.2)	5903 (75.8)
II-IV	3694 (23.8)	1883 (24.2)
Cardiac arrest at admission	128 (0.8)	77 (1.0)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AMI classification		
STEMI	12051 (75.7)	5991 (75.2)
NSTEMI	3874 (24.3)	1971 (24.8)
Anterior wall involvement	7406 (47.7)	3696 (47.5)
Laboratory results		
Creatinine, $\mu\text{mol/L}$	74.90 (62.00, 90.00)	74.60 (62.00, 90.40)
Creatinine clearance, ml/min	83.83 (61.61, 109.00)	83.70 (61.52, 108.71)
Hemoglobin, g/L	136.23 \pm 21.09	136.07 \pm 20.94
Leukocyte count, $\times 10^9/\text{L}$	10.09 \pm 3.69	10.04 \pm 3.60
LVEF, %	53.84 \pm 10.07	53.81 \pm 10.08
In-hospital treatment		
PCI	8951 (57.9)	4432 (57.2)
CABG	127 (0.8)	76 (1.0)
Adverse events during hospitalization		
New-onset heart failure	2082 (13.5)	1035 (13.4)
Recurrent myocardial ischemia	384 (2.5)	166 (2.2)
Recurrent myocardial infarction	61 (0.4)	22 (0.3)
Stroke	90 (0.6)	40 (0.5)
Other bleeding events	236 (1.5)	121 (1.6)
Medications at discharge		
Antiplatelet therapy		
Dual antiplatelet therapy	13212 (87.6)	6571 (87.1)
Single antiplatelet therapy	1261 (8.4)	648 (8.6)
None	603 (4.0)	327 (4.3)
Statins	13846 (91.8)	6976 (92.4)
β blockers	10341 (68.6)	5006 (66.3)
ACEI/ARB	8642 (57.3)	4326 (57.3)
Hospital level		
Province level	5516 (34.6)	2728 (34.3)
Prefecture level	8740 (54.9)	4371 (54.9)
County level	1668 (10.5)	863 (10.8)

Values are shown as mean \pm standard deviation, median (interquartile range), or number (%)

1
2
3 without imputation of missing data. BMI, body mass index; PCI, percutaneous coronary
4 intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary
5 disease; AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial
6 infarction; NSTEMI, non-ST-segment elevation myocardial infarction; LVEF, left ventricular
7 ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II
8 receptor blocker.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental Table 3. Baseline characteristics, medications, and outcomes of cohorts for developing and validating 2-year prognostic model

Variables	Derivation cohort (n=12136)	Validation cohort (n=6067)
Demographics		
Age, yrs	62.08±12.28	62.26±12.20
Female	2967 (24.4)	1459 (24.0)
BMI, kg/m ²	24.12±3.02	24.11±3.01
Medical history		
Diabetes	2213 (19.0)	1146 (19.6)
Hypertension	6021 (50.6)	3011 (50.7)
Hyperlipidemia	760 (7.2)	382 (7.2)
Current smoker	5565 (46.3)	2737 (45.5)
Prior angina pectoris	3173 (28.0)	1571 (27.8)
Prior myocardial infarction	821 (7.2)	420 (7.3)
Prior heart failure	243 (2.1)	120 (2.1)
Prior stroke	1038 (8.8)	572 (9.7)
Prior peripheral artery disease	72 (0.6)	30 (0.5)
Prior PCI	562 (4.8)	293 (5.0)
Prior CABG	38 (0.3)	25 (0.4)
Prior renal dysfunction	130 (1.1)	56 (1.0)
COPD	221 (1.9)	114 (2.0)
Presenting characteristics		
Symptom onset to admission time		
0-6h	5725 (47.6)	2798 (46.5)
>6h	6298 (52.4)	3216 (53.5)
Heart rate, beats/min	77±18	78±18
Systolic blood pressure	129.61±25.30	130.00±25.52
Killip class		
I	9163 (76.2)	4589 (76.3)
II-IV	2859 (23.8)	1424 (23.7)
Cardiac arrest at admission	95 (0.8)	62 (1.0)
AMI classification		

STEMI	9215 (75.9)	4560 (75.2)
NSTEMI	2921 (24.1)	1507 (24.8)
Anterior wall involvement	5743 (47.7)	2843 (47.2)
Laboratory results		
Creatinine, $\mu\text{mol/L}$	74.00 (61.80, 89.10)	73.90 (61.40, 89.60)
Creatinine clearance, ml/min	84.53 (62.60, 109.58)	84.92 (63.22, 110.16)
Hemoglobin, g/L	136.37 \pm 20.82	136.39 \pm 20.79
Leukocyte count, $\times 10^9/\text{L}$	10.09 \pm 3.65	10.02 \pm 3.52
LVEF, %	54.08 \pm 10.00	54.01 \pm 9.94
In-hospital treatment		
In-hospital PCI	6998 (58.4)	3468 (57.7)
In-hospital CABG	87 (0.7)	50 (0.8)
Adverse events during hospitalization		
New-onset heart failure	1616 (13.5)	805 (13.5)
Recurrent myocardial ischemia	281 (2.3)	125 (2.1)
Recurrent myocardial infarction	37 (0.3)	18 (0.3)
Stroke	65 (0.5)	29 (0.5)
Other bleeding events	183 (1.5)	94 (1.6)
Medications within 30 days		
Antiplatelet therapy		
Dual antiplatelet therapy	10518 (86.7)	5287 (87.1)
Single antiplatelet therapy	1292 (10.6)	610 (10.1)
None	326 (2.7)	170 (2.8)
Statins	11486 (94.6)	5736 (94.5)
β blockers	8751 (72.1)	4347 (71.6)
ACEI/ARB	7221 (59.5)	3591 (59.2)
Hospital level		
Province level	3876 (31.9)	1956 (32.2)
Prefecture level	6947 (57.2)	3461 (57.0)
County level	1313 (10.8)	650 (10.7)

Values are shown as mean \pm standard deviation, median (interquartile range), or number (%) without imputation of missing data. BMI, body mass index; PCI, percutaneous coronary

1
2
3 intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary
4 disease; AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial
5 infarction; NSTEMI, non-ST-segment elevation myocardial infarction; LVEF, left ventricular
6 ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II
7 receptor blocker.
8
9

Supplemental Table 4. Univariable analysis of 30-day mortality

	Unadjusted HR (95% CI)	P value
Age (per 1 year increase)	1.066 (1.052, 1.080)	<0.0001
Women (vs men)	1.662 (1.233, 2.241)	0.0009
BMI (per 1kg/m ² increase)	0.893 (0.850, 0.939)	<0.0001
Diabetes (vs no)	1.545 (1.123, 2.126)	0.0075
Hypertension (vs no)	1.289 (0.958, 1.734)	0.0930
Hyperlipidemia (vs no)	0.749 (0.406, 1.384)	0.3547
Current smoking (vs no)	0.406 (0.293, 0.563)	<0.0001
Prior angina pectoris (vs no)	1.324 (0.972, 1.803)	0.0754
Prior myocardial infarction (vs no)	1.177 (0.709, 1.954)	0.5284
Prior heart failure (vs no)	5.078 (3.166, 8.144)	<0.0001
Prior stroke (vs no)	2.627 (1.842, 3.747)	<0.0001
Prior PCI (vs no)	0.814 (0.400, 1.659)	0.5717
Prior CABG (vs no)	—	—
Prior renal dysfunction (vs no)	1.596 (0.587, 4.338)	0.3591
COPD (vs no)	3.208 (1.744, 5.901)	0.0002
Prior peripheral artery disease (vs no)	—	—
Symptom onset to admission time (vs 0-6h)		
>6h	1.947 (1.431, 2.649)	<0.0001
Heart rate (per 1 beat increase)	1.024 (1.018, 1.029)	<0.0001
Systolic blood pressure (per 1mmHg increase)	0.994 (0.988, 1.000)	0.0358
Killip class (vs I)		
II-IV	3.980 (2.990, 5.298)	<0.0001
Cardiac arrest at admission (vs no)	1.921 (0.614, 6.011)	0.2620
NSTEMI (vs STEMI)	1.230 (0.898, 1.686)	0.1977
Anterior wall involvement (vs no)	1.255 (0.943, 1.671)	0.1185
Creatinine clearance (vs >90 ml/min)		
60-90	1.805 (1.222, 2.666)	0.0030
≤60	4.252 (2.985, 6.058)	<0.0001
Hemoglobin (per 1g/L increase)	0.988 (0.983, 0.993)	<0.0001
Leukocyte count (per 10 ⁹ /L increase)	1.055 (1.023, 1.088)	0.0006

1			
2			
3	LVEF (per 1% increase)	0.938 (0.923, 0.952)	<0.0001
4			
5	In-hospital PCI (vs no)	0.220 (0.157, 0.308)	<0.0001
6			
7	In-hospital CABG (vs no)	1.277 (0.317, 5.145)	0.7308
8			
9	New-onset heart failure during hospitalization (vs no)	7.204 (5.414, 9.585)	<0.0001
10			
11	Recurrent myocardial ischemia during hospitalization (vs no)	6.028 (3.938, 9.228)	<0.0001
12			
13	Recurrent myocardial infarction during hospitalization (vs no)	13.299 (6.752, 26.195)	<0.0001
14			
15			
16	Stroke during hospitalization (vs no)	2.908 (0.934, 9.052)	0.0654
17			
18	Other bleeding events during hospitalization (vs no)	4.109 (2.235, 7.558)	<0.0001
19			
20	Antiplatelet therapy at discharge (vs dual therapy)		
21			
22	Single antiplatelet therapy	1.344 (0.762, 2.372)	0.3024
23			
24	none	5.158 (3.468, 7.672)	<0.0001
25			
26	Statins at discharge (vs no)	3.180 (2.246, 4.502)	<0.0001
27			
28	β blockers at discharge (vs no)	1.483 (1.105, 1.991)	0.0087
29			
30	ACEI/ARB at discharge (vs no)	1.481 (1.088, 2.017)	0.0128

BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HR, hazard ratio; CI, confidence interval.

Supplemental Table 5. Univariable analysis of mortality after 30 days

	Unadjusted HR (95% CI)	P value
Age (per 1 year increase)	1.084 (1.076, 1.092)	<0.0001
Women (vs men)	1.947 (1.679, 2.259)	<0.0001
BMI (per 1kg/m ² increase)	0.895 (0.872, 0.919)	<0.0001
Diabetes (vs no)	1.571 (1.328, 1.857)	<0.0001
Hypertension (vs no)	1.533 (1.321, 1.779)	<0.0001
Hyperlipidemia (vs no)	0.631 (0.443, 0.900)	0.0111
Current smoking (vs no)	0.423 (0.359, 0.498)	<0.0001
Prior angina pectoris (vs no)	1.318 (1.131, 1.536)	0.0004
Prior myocardial infarction (vs no)	2.064 (1.657, 2.570)	<0.0001
Prior heart failure (vs no)	5.964 (4.685, 7.594)	<0.0001
Prior stroke (vs no)	2.013 (1.651, 2.455)	<0.0001
Prior PCI (vs no)	1.122 (0.817, 1.540)	0.4770
Prior CABG (vs no)	1.656 (0.618, 4.433)	0.3156
Prior renal dysfunction (vs no)	4.383 (2.969, 6.470)	<0.0001
COPD (vs no)	2.897 (2.076, 4.044)	<0.0001
Prior peripheral artery disease (vs no)	2.273 (1.197, 4.314)	0.0122
Symptom onset to admission time (vs 0-6h)		
>6h	1.497 (1.287, 1.742)	<0.0001
Heart rate (per 1 beat increase)	1.021 (1.018, 1.024)	<0.0001
Systolic blood pressure (per 1mmHg increase)	1.005 (1.002, 1.008)	0.0005
Killip class (vs I)		
II-IV	3.225 (2.792, 3.726)	<0.0001
Cardiac arrest at admission (vs no)	1.068 (0.478, 2.388)	0.8724
NSTEMI (vs STEMI)	2.395 (2.070, 2.771)	<0.0001
Anterior wall involvement (vs no)	1.210 (1.047, 1.398)	0.0096
Creatinine clearance (vs >90 ml/min)		
60-90	1.725 (1.405, 2.119)	<0.0001
≤60	5.193 (4.328, 6.231)	<0.0001
Hemoglobin (per 1g/L increase)	0.980 (0.978, 0.983)	<0.0001
Leukocyte count (per 10 ⁹ /L increase)	1.010 (0.990, 1.030)	0.3333

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

LVEF (per 1% increase)	0.948 (0.941, 0.955)	<0.0001
In-hospital PCI (vs no)	0.207 (0.175, 0.246)	<0.0001
In-hospital CABG (vs no)	0.421 (0.106, 1.674)	0.2184
New-onset heart failure during hospitalization (vs no)	3.418 (2.932, 3.984)	<0.0001
Recurrent myocardial ischemia during hospitalization (vs no)	2.653 (1.949, 3.610)	<0.0001
Recurrent myocardial infarction during hospitalization (vs no)	1.773 (0.659, 4.771)	0.2565
Stroke during hospitalization (vs no)	3.455 (1.991, 5.996)	<0.0001
Other bleeding events during hospitalization (vs no)	2.233 (1.486, 3.356)	0.0001
Recurrent myocardial infarction within 30 days (vs no)	3.032 (1.130-8.134)	0.0276
Heart failure worsening within 30 days (vs no)	4.790 (3.631, 6.319)	<0.001
Antiplatelet therapy within 30 days (vs dual antiplatelet therapy)		
Single antiplatelet therapy	2.147 (1.779, 2.591)	<0.0001
none	4.371 (3.385, 5.643)	<0.0001
Statins within 30 days (vs no)	2.454 (1.960, 3.073)	<0.0001
β blockers within 30 days (vs no)	1.594 (1.374, 1.850)	<0.0001
ACEI/ARB within 30 days (vs no)	1.153 (0.997, 1.333)	0.0546

BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HR, hazard ratio; CI, confidence interval.

Supplemental Table 6. Discrimination of 30-day prognostic nomogram in subgroups of patients

Subgroup	Sample size	C statistic (95% CI)
Age, yrs		
≤75	4766	0.74 (0.65-0.84)
>75	935	0.83 (0.71-0.94)
Sex		
Male	4359	0.79 (0.69-0.88)
Female	1342	0.75 (0.62-0.88)
Diabetes		
Yes	1106	0.81 (0.62-1.00)
No	4431	0.78 (0.70-0.87)
Diagnosis		
STEMI	4302	0.77 (0.68-0.86)
NSTEMI	1399	0.83 (0.72-0.93)
In-hospital PCI		
Yes	3498	0.76 (0.63-0.88)
No	2203	0.76 (0.66-0.85)
Hospital level		
Province level	1984	0.78 (0.66-0.90)
Prefecture level	3168	0.80 (0.70-0.90)
County level	549	0.74 (0.51-0.97)

STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CI, confidence interval.


Supplemental Table 7. Discrimination of 2-year prognostic nomogram in subgroups of patients

Subgroup	Sample size	C statistic (95% CI)
Age, yrs		
≤75	3766	0.79 (0.75-0.83)
>75	695	0.66 (0.62-0.71)
Sex		
Male	3412	0.83 (0.80-0.86)
Female	1049	0.75 (0.70-0.80)
Diabetes		
Yes	845	0.81 (0.76-0.86)
No	3496	0.81 (0.78-0.84)
AMI classification		
STEMI	3364	0.81 (0.78-0.84)
NSTEMI	1097	0.81 (0.76-0.85)
In-hospital PCI		
Yes	3104	0.82 (0.78-0.87)
No	1357	0.72 (0.68-0.76)
Hospital level		
Province level	1460	0.83 (0.78-0.88)
Prefecture level	2552	0.81 (0.77-0.84)
County level	449	0.78 (0.70-0.85)


AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CI, confidence interval.

II. Supplemental Figures.

Supplemental Figure 1. Flowchart of this study




Supplemental Figure 2. Martingale residual plots for testing the linearity assumption before developing the 30-day model




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Supplemental Figure 3. Martingale residual plots for testing the linearity assumption before developing the 2-year model




Supplemental Figure 4. Schoenfeld residual plots for testing the proportional hazards assumption before developing the 30-day model





Supplemental Figure 5. Schoenfeld residual plots for testing the proportional hazards assumption before developing the 2-year model





Supplemental Figure 6. Kaplan-Meier curve for patients after AMI hospitalization




Supplemental Figure 7. Density plots for all-cause death and recurrent myocardial infarction during follow-up



Supplemental Figure 8. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 1





Supplemental Figure 9. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 2




Supplemental Figure 10. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 3


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Supplemental Figure 11. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 4




Supplemental Figure 12. Variable selection by LASSO method for 30-day prognostic model in imputation dataset 5




Supplemental Figure 13. Relative importance of selected predictors for 30-day mortality




Supplemental Figure 14. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 1



Supplemental Figure 15. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 2





Supplemental Figure 17. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 4




Supplemental Figure 18. Variable selection by LASSO method for 2-year prognostic model in imputation dataset 5



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Supplemental Figure 19. Relative importance of selected predictors for 2-year mortality



Supplemental Figure 20. Comparisons of clinical utility between models with or without adverse events and medications





Supplemental Figure 21. Comparisons of clinical utility between models with or without hospital level




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental Figure 22. Comparisons of clinical utility between models and GRACE 1.0 score




Supplemental Figure 23. Comparisons of clinical utility between models and GRACE 2.0 score




Supplemental Figure 24. Calibration curves of 30-day prognostic nomogram

A




B




Supplemental Figure 25. Calibration curves of 2-year prognostic nomogram

A



B



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
TRIPOD Checklist: Prediction Model Development

Section	Item	Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract				
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.		
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.		
Introduction				
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.		
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.		
Methods				
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.		
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.		
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.		
	5b	Describe eligibility criteria for participants.		
	5c	Give details of treatments received, if relevant.		
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.		
	6b	Report any actions to blind assessment of the outcome to be predicted.		
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.		
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.		
Sample size	8	Explain how the study size was arrived at.		

Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.		
Statistical analysis methods	10a	Describe how predictors were handled in the analyses.		
	10b	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.		
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.		
Risk groups	11	Provide details on how risk groups were created, if done.		
Results				
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.		
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.		
Model development	14a	Specify the number of participants and outcome events in each analysis.		
	14b	If done, report the unadjusted association between each candidate predictor and outcome.		
Model specification	15a	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).		
	15b	Explain how to use the prediction model.		
Model performance	16	Report performance measures (with CIs) for the prediction model.		
Discussion				
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).		
Interpretation	19b	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.		
Implications	20	Discuss the potential clinical use of the model and implications for future research.		
Other information				
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.		
Funding	22	Give the source of funding and the role of the funders for the present study.		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



For peer review only